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Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS)
characterized by demyelination and loss of oligodendrocytes (OLGs), the CNS myelinproducing cells. Thus, understanding the mechanisms that control OLG development can
provide valuable knowledge regarding remyelination therapies for MS. This disease is
thought to result from an autoimmune attack towards myelin. FTY720, an
immunomodulator under evaluation for MS treatment is a sphingosine-1-phosphate (S1P)
analog. We found before that S1P plays a crucial role in the NT-3-mediated survival of
OLGs, an observation that led us to investigate whether FTY720 could have any effect on
xiv

xv
these cells. Our studies demonstrate that FTY720 indeed has a direct effect on OLG
progenitors, protecting them from apoptotic death through a mechanism involving ERK1/2
and Akt activation. However, another key finding of our study was that this drug arrested
OLG differentiation, an effect counteracted by NT-3 which not only enhanced the survival
of OLG progenitors but also stimulated their maturation. Furthermore, NT-3 induced an
increase in myelin basic protein (MBP) levels in the absence of effects on MBP gene
promoter activation or mRNA expression. These observations suggested that NT-3 upregulated MBP levels by a posttranscriptional mechanism raising the question of whether
this neurotrophin could have a more general positive effect on the expression of other OLG
proteins. In agreement with this idea, we found that NT-3 also induced the expression of
the myelin proteins MAG and MOG. Additionally, [35S]-Methionine labeling indicated a
50% increase in de novo protein synthesis following only a 15 min exposure to NT-3. Such
a rapid increase in protein synthesis reinforced the idea that NT-3 plays a crucial role
regulating protein expression by posttranscriptional mechanisms.

In support of this

possibility, we found that NT-3 stimulated the phosphorylation of the initiation factor
eIF4E and its inhibitory partner 4EBP1, both essential players in mediating cap-dependent
protein synthesis. This stimulation involved the activation of ERK1/2 and PI3K/mTOR
mediated signaling pathways. To our knowledge, this is the first study on the regulation of
translation initiation in OLGs and the first report describing the potential role of NT-3 as
an activator of initiation.

CHAPTER 1
INTRODUCTION

The nervous system of a living organism, whether vertebrate or invertebrate, has
long been considered a biological enigma that poses multiple unanswered questions to the
scientific community. Starting right at conception, the development of this system is
controlled by finely tuned intrinsic genetic cues as well as environmental signals.
Moreover, developing cells possess the ability to interact with and specifically influence
the evolution of other cells within the nervous system either directly or indirectly. By the
concurrent generation of new cells and elimination of those in excess, this process of
„sculpting and remodeling‟ culminates into a highly complex system that directs the
functioning of the entire organism by a myriad of both internal and peripheral
connections.
The basic cellular units of the nervous system are the neurons and the glia.
Although neurons are considered to be the main functional components of the nervous
system due to their ability to generate electrical impulses, glial cells heavily outnumber
them, constituting approximately 90% of cells in the human brain. The term „glia‟ broadly
encompasses five types of cells: astrocytes, oligodendrocytes, Schwann cells, ependymal
cells and microglia. In a broad sense, glial cells provide trophic support for the neurons
and also protect them from external insults. Thus, glial cells have traditionally been
1
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looked upon as passive contributors to nervous system structure and function by years of
„neuron-centric‟ scientific dogma. However, this role is increasingly being challenged as
several studies point towards a more electrically active function of glia, particularly
astrocytes, in synapse formation and subsequent transmission of nerve impulses (Araque
et al. 1999; Haydon and Carmignoto 2006; Ransom et al. 2003; Volterra and Meldolesi
2005). The finding that the other major glial cell, the oligodendrocyte (OLG) expresses
NMDA receptors at all stages of its development which are activated during specific
pathological conditions (Karadottir et al. 2005; Salter and Fern 2005) has shed light on yet
another potential function of these cells in mediating nerve transmission. Furthermore,
recent studies have discovered the presence of a subset of OLG precursors that are capable
of generating action potentials (Karadottir et al. 2008), a finding that challenges the idea
that only neurons are capable of electrical activity in the central nervous system (CNS). In
addition to these newly found electrical properties of OLGs, their foremost role is the
synthesis and maintenance of the myelin sheath in the CNS. In the peripheral nervous
system (PNS), the Schwann cell forms myelin by wrapping itself around axonal segments.
The following sections will provide a brief review of the current knowledge regarding
myelin, particularly CNS myelin.

Myelin formation and structure
Myelin, a term coined by Rudolph Virchow (Virchow 1854) is a specialized
multilamellar structure, generated by glial cells, that wraps around the axons in the
vertebrate nervous system. The myelin sheath is found in all classes of vertebrates with
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the exception of the jawless fish like hagfish and lampreys (Bullock et al. 1984) in which
case, the axons are not myelinated but are still surrounded by glial cells. Interestingly, a
form of axonal ensheathment is present in some invertebrates in which glial cells give rise
to a superficial membrane structure resembling vertebrate myelin (Colman 1996;
Waehneldt 1990).
Myelin can be regarded as a three-dimensional structure formed by the extension
and concentrical wrapping around the axons of the oligodendroglial membrane in the CNS
and Schwann cell membrane in the PNS (Figure 1.1). In both cases, extrusion of the
cytoplasm and subsequent compaction of the wrapping glial membrane result in a
continuous, multilamellar sheath or „myelin internode‟ which is 150-200 µm long (Butt
and Ransom 1989).

Adjacent myelin internodes delimit the presence of unmyelinated

areas of the axons known as „nodes of Ranvier‟. Importantly, while each Schwann cell
forms a single myelin internode in a single axon, each OLG can myelinate multiple axons
and form several myelin internodes per axon (Baumann and Pham-Dinh 2001).
When visualized by electron microscopy (Figure 1.1), myelin appears as a series
of alternating dark and less dark lines separated by lighter zones. The dark line, formed by
the fusion of the inner or cytosolic surfaces of the cell membrane, is known as the „major
period line‟. The less dark line, „the intraperiod or minor dense line‟, is formed by the
close apposition of the outer leaflets of the membrane. Since the membranes do not
actually fuse, the intraperiod line can be resolved as a double line when observed at higher
magnification. The periodicity, the distance between two successive major period lines, is
119 angstroms in the PNS and 107 angstroms in the CNS.

4

Fig 1.1: Formation of the myelin sheath (A) Myelinating glial cells, oligodendrocytes
(OLGs) in the CNS or Schwann cells in the PNS form the myelin sheath by enwrapping
their membrane several times around the axon. Adjacent myelin segments (internodes)
cover the axon at intervals, leaving bare gaps called nodes of Ranvier. OLGs can
myelinate multiple axons and several internodes per axon, whereas Schwann cells
myelinate a single internode in a single axon. Modified from Sebastian Poliak & Elior
Peles, Nature Reviews Neuroscience, 2003. (B) The appearance of CNS myelin if it were
unrolled from the axon. The myelin internode forms a sheet surrounded by a continuous
loop of oligodendroglial cytoplasm. The drawing on the right shows that the compact
myelin region is formed by the fusion of the cytoplasmic surfaces of the membrane. (C)
Electron micrograph of a myelinated fiber from an adult dog spinal cord showing the
typical multilamellar structure. Modified from Basic Neurochemistry, edited by Siegel,
Albers, Brady and Price, Elsevier, 2006.
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Areas of uncompacted myelin within the internode provide continuity in the
cytoplasm of the myelinating cell that allows for the transport of myelin components
between the cell and the axonal membrane. Electron microscopy shows the presence of
microtubules and mitochondria in these cytoplasmic channels, presumably for transport
and energy requirements respectively. In some areas, they also contain free polysomes and
smooth endoplasmic reticulum (ER) for local protein biosynthesis. These loops of
cytoplasm that are present predominantly at the lateral ends of the internode are referred
to as „paranodal loops‟ (Figure 1.2). These loops establish membrane complexes with the
periaxonal membrane to form „transverse bands‟ that are associated with cytoskeletal
filaments and appear to tighten the connection between the axon and paranode (Ichimura
and Ellisman 1991). Conversely, myelin in the internodes is separated from the axon by
an extracellular gap of periaxonal space. In the PNS, Schmidt-Lanterman incisures are
commonly found within the compacted myelin. Thus, they are present as oblique funnellike clefts that extend across the entire thickness of the sheath as opposed to the lateral
positioning of the paranodal loops of CNS myelin. Like the paranodal loops, the SchmidtLanterman clefts act as a connection between the cytoplasm on the outside of the sheath
and that on the inside part. Another specialization of the myelin sheath is the radial
component that is found in the CNS and has been described as a junctional complex
within internodal myelin acting as a scaffold or latticework to stabilize the membrane. In
addition to myelin proteins and galactolipids, this region is rich in cytoskeletal proteins,
particularly actin and tubulin which could explain its role in strengthening the junctionmembrane interface (Karthigasan et al. 1994).

7

Fig 1.2: The myelin sheath forms axonal domains which are essential for impulse
conduction. (A) An electron micrograph from a longitudinal section from rat spinal dorsal
root nerve showing the node of Ranvier flanked by internodal segments insulated by
layers of compact myelin. Each layer of myelin terminates in a series of loops adjacent to
the node of Ranvier (the paranodal loops) (b) Three axonal domains are defined by axon
interactions with myelinating glia: the Na + channel-enriched node of Ranvier, the adjacent
paranode where the loops of myelin adhere to the axon through cell-adhesion molecules
linked to the axonal cytoskeleton, the juxtaparanode which contains K+ channels and the
internode sealed by compacted layers of myelin membrane to restrict transmembrane ion
currents to the nodal region. Modified from Fields, RD, Trends Neuroscience, 2008
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As described below, the unique structure and the high lipid content of the myelin
membrane determine its crucial role as a facilitator in nerve transmission. In addition, both
myelinating glial cells and the myelin membrane exert regulatory functions that
coordinate myelination with axonal growth and participate in axonal protection.

Myelin, an essential requirement for rapid nerve transmission and axonal integrity
In contrast to the invertebrate nervous system where rapid nerve transmission is
dependent on increased axonal caliber; the major advantages offered by the myelin sheath
in vertebrates are high speeds of conduction along with increased fidelity and space
economy. If it were not for the presence of myelin around the axons, the human spinal
cord would have to be as thick as an average-sized tree trunk to maintain equivalent
conduction velocities as achieved by myelinated fibers. As part of this process, the highly
hydrophobic and compact myelin membrane acts as an insulating sheath to facilitate
axonal conduction. In unmyelinated fibers, local circuits of ion currents flow into the
active region of the axolemma to the adjacent portion of the membrane producing
segments of depolarization along the axon in a continuous fashion (Fig 1.3A). As
described in the previous section, in myelinated axons, the axonal membrane is exposed to
the extracellular space only at the regions of interruption of the myelin sheath along the
axon, i.e at the nodes of Ranvier (Fig 1.2B). Excitation of the axonal membrane at the
node results in the generation of a local circuit that cannot flow through the high
resistance myelin sheath at the adjacent internodes. Therefore, the impulse can only flow
through the membrane at the next node and cause depolarization. Moreover, the myelin

10

Fig 1.3: Comparison between conduction in a myelinated axon versus an
unmyelinated axon. Arrows show the flow of action potential in local circuits into the
active region of the membrane. (A) In unmyelinated fibers, the current flows throughout
the length of the axon in contrast to (B) myelinated fibers where the current jumps
between adjacent nodes resulting in saltatory conduction. Modified from Basic
Neurochemistry, edited by Siegel, Albers, Brady and Price, Elsevier, 2006.
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sheath has low capacitance that results in a lower energy requirement to depolarize the
rest of the axonal membrane between the nodes. Since this flow of electrical impulses
„jumps‟ from node to node, it is referred to as „saltatory‟ conduction (from the Latin word
„saltare‟ meaning to jump).
In addition to its function in nerve transmission, several lines of evidence indicate
that the myelin membrane also plays a crucial role in axonal development. It was shown
that myelination can extrinsically regulate axonal caliber in the developing optic nerve
(Sanchez et al. 1996). Similarly, the regulation of axonal caliber by myelination was
evident from the comparison between axonal caliber in myelinated regions with the
nonmyelinated initial segment of dorsal root ganglion axons (Hsieh et al. 1994). Both
neurofilament spacing and phosphorylation, two determinants of axonal radial growth,
were decreased in nonmyelinated regions which correlated with the observed reduced
axonal caliber in these areas.
Moreover, in myelinated axons, the nodes of Ranvier are abundantly populated
with voltage-gated sodium channels which are responsible for the intense inward sodium
currents (Utzschneider et al. 1993; Waxman and Ritchie 1985). Importantly, different
studies have shown that both myelinating glia and myelin itself are responsible for
inducing and maintaining this selective distribution of ion channels at the nodes and
paranodes (Dupree et al. 1999; Honke et al. 2002; Ishibashi et al. 2002; Marcus et al.
2002; Schafer and Rasband 2006; Shaw et al. 1996), an essential requirement for saltatory
conduction. The axonal domains determined by the myelin sheath are depicted in figure
1.2.

13
Furthermore, myelin is also crucial for the maintenance and survival of axons. In
mice lacking two major myelin proteolipids: myelin proteolipid protein (PLP) and its
splice isoform DM20, normal compaction of the myelin sheath is accompanied by
progressive axonal swellings and degeneration, suggesting that these constituents of
myelin are crucial for maintaining axonal stability even in the presence of normal
myelination (Griffiths et al. 1998). Moreover, loss of the gene encoding the enzyme 2',3'cyclic nucleotide 3'-phosphodiesterase (CNP), which is a widely used marker of myelinforming glial cells, resulted in severe axonal loss inspite of normal assembly of the myelin
sheath (Lappe-Siefke et al. 2003). In addition, replacement in mice of the major CNS
myelin protein PLP with the major PNS myelin protein produced a normal PNS pattern of
myelination in the CNS but was accompanied by profound axonal pathology and
degeneration (Yin et al. 2006). Similarly, several other studies have illustrated the
occurrence of axonal loss due to deletion or mutations in genes encoding myelin proteins
and enzymes that synthesize myelin galactolipids, even in the absence of myelin defects
(Dupree et al. 1999; Garbern et al. 2002; Kassmann and Nave 2008; Uschkureit et al.
2000).
During normal development, the presence of the myelin sheath is crucial to the
proper assembly of the axon as illustrated above. However, myelin also has inhibitory
roles on neurite growth. This inhibition assists in the formation of late-developing tracts
and inhibition of plasticity in the adult CNS (Baumann and Pham-Dinh 2001). OLGassociated neurite growth inhibitors in the already myelinated areas of the CNS could
channel late-growing tracts by exerting a „guard-rail‟ function (Schwab and Schnell
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1991). This inhibitory ability of myelin poses a major problem following mammalian
CNS injury and particularly spinal cord traumatic insult in humans due to the myelininduced block on regeneration of lesioned axons in addition to reactive astrocytosis (Hou
et al. 2008). It was long known that the permissiveness of the environment was a major
determinant for CNS axonal repair (Cajal 1928; Tello 1911). It was demonstrated that
most CNS neurons are able to regenerate a lesioned axon in the environment of a
peripheral nerve transplant (Richardson et al. 1980) whereas peripheral nerves fail to
regenerate in a CNS glia environment (David and Aguayo 1981). The use of multiple
grafts of peripheral nerve tissue bridging the lesion site and the grey matter was shown to
permit extensive CNS axon growth and to restore partial function to a completely
transected spinal cord (Fawcett and Geller 1998). A new concept of a neurite growth
inhibitor emerged after extensive investigations of the biological mechanism that could
explain this difference between CNS and PNS neuronal regeneration (Schwab and
Thoenen 1985). Central myelin and differentiated OLGs from the adult CNS were
subsequently recognized as being responsible for the inhibition of neurite outgrowth and
were shown to cause growth cone collapse in culture (Bandtlow et al. 1990). Two related
protein fractions of 35 and 250 kDa were found to contain the myelin-associated
inhibitory activity. These two proteins are membrane-bound and highly enriched in
mammalian CNS myelin and OLGs, but minor in PNS myelin (Caroni and Schwab
1988b). A monoclonal antibody (MAb IN-1) has been generated and shown in vitro to
have neutralizing properties against the inhibitory activity of OLGs and myelin (Caroni
and Schwab 1988a). In vivo application of MAb IN-1 after a complete bilateral transection
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of the corticospinal tracts in spinal cord resulted in some regeneration on a small
percentage of cortical tract axons (Schnell and Schwab 1993). However, MAb IN-1
treatment after unilateral transection of the corticospinal tract in the brain stem was shown
to induce significant collateral sprouting of both intact and lesioned corticospinal and
corticobulbar nerve fibers both above and below the lesion site (Thallmair et al. 1998).
Remarkably, this improvement in structural plasticity was associated with a functional
recovery of forelimb function contralateral to the lesion (Thallmair et al. 1998). Another
CNS-inhibitory myelin protein produced by OLGs is myelin-associated glycoprotein
(MAG). MAG is inhibitory to a number of different types of neurons. MAG is considered
to be inhibitory rather than a nonpermissive protein as it is able to cause growth cone
collapse in vitro (Li et al. 1996). Moreover, the soluble extracellular domain of MAG
(dMAG), released in abundance from myelin has been shown to inhibit axonal
regeneration in vitro (Li et al. 1996). Interestingly, early during development, MAG
appears to play a crucial role in mediating bidirectional signals that coordinate OLG
development with axonal radial growth (Quarles 2007). Thus, it is now clear that myelin
plays crucial functions that expand well beyond its classical role in nerve conduction,
coordinating glial development with axonal growth and maintaining axonal integrity.

Molecular composition of myelin
The dry mass of both PNS and CNS myelin is made up of a high proportion of
lipid (70-85%) and a significantly lower proportion of protein (15-30%). This is in
remarkable contrast with most biological membranes which generally have a higher
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concentration of proteins. This unique composition of myelin (richness of lipids and low
water content) is partly responsible for its efficiency in supporting rapid nerve conduction.
Mammalian myelin contains cholesterol, phospholipids and glycolipids in ratios ranging
from 4:3:2 to 4:4:2.
glycosphingolipids,

A major characteristic of myelin is its high content of

particularly

galactocerebrosides

(GalC)

which

consist

of

galactosylceramides and their sulfated derivatives, sulfatides. The monoclonal antibody
O4 which is commonly used as a surface marker of immature oligodendrocytes is, in fact,
reactive to sulfatides (Bansal et al. 1989) Thus, GalC can be considered to be the most
typical of myelin lipids and they represent 20% of the lipid dry weight of myelin. In
addition to the major galactolipids, there are also several minor ones such as fatty esters of
cerebrosides and galactosyldiglycerides ((Pieringer et al. 1977; Theret et al. 1988).
The major proteins of CNS myelin are myelin basic protein (MBP) and PLP
(including its isoform DM20). They are low molecular weight proteins and form 80% of
the total protein content of myelin (Morell et al. 1973). Figure 1.4 shows the proposed
arrangement of these two proteins within the myelin architecture of the CNS. Other major
myelin proteins include the enzyme 2‟,3‟-cyclic nucleotide phosphohydrolase (CNP)
(Wolfgram 1966), MAG and the myelin oligodendrocyte glycoprotein (MOG). Among
the myelin proteins, MBP has been extensively studied as an identifying feature of
myelinating OLGs. In Chapter 3, this thesis presents a series of studies investigating MBP
expression in OLGs in response to neurotrophin-3 (NT-3) treatment. Therefore, the next
section will delve further into the salient characteristics of this important myelin protein.
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Fig 1.4: The major structural proteins of CNS myelin. The apposition of the
extracellular (Ext) surfaces of the OLG forms the intraperiod (IP) line. The apposition of
the cytoplasmic (Cyto) surfaces of the membranes of the OLG forms the major dense
(MD) line. Modified from Basic Neurochemistry, edited by Siegel, Albers, Brady and
Price, Elsevier, 2006
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Myelin basic protein
MBP, which constitutes 40% of the protein in myelin, belongs to a family of
alternatively spliced, highly charged extrinsic membrane proteins which bind negatively
charged lipids, specifically phosphatidylserine residues (Greenfield et al. 1973; Zeller et
al. 1984). MBP was first isolated from white matter in the late 1960s and its amino acid
composition determined soon after (Carnegie 1971; Carnegie et al. 1974; Eylar 1970;
Kibler et al. 1969). Initial studies in rodents determined that the protein existed in multiple
isoforms (Barbarese et al. 1977; Martenson et al. 1971; Martenson et al. 1972) which were
shown to be produced by the translation of separate mRNAs (Yu and Campagnoni 1982).
Interestingly, these MBP transcripts were found to be generated through alternative
splicing of the Golli (genes of oligodendrocyte lineage)-MBP gene (Aruga et al. 1991; de
Ferra et al. 1985; Kamholz et al. 1986; Newman et al. 1987; Roth et al. 1987; Takahashi et
al. 1985). The Golli-MBP gene is approximately 105 Kb long in the mouse and around
180 Kb in humans (Campagnoni et al. 1993; Pribyl et al. 1993) and contains three
transcription start sites and at least 11 different exons. This gene encodes two families of
proteins: the classic MBPs which are found in myelin and OLGs, as well as the the golli
proteins which are surprisingly found in both OLGs and cells of the immune system. The
classic MBP mRNAs are predominantly generated by activation of transcription start site
3. This site is extremely active in myelinating cells although low levels of expression of
the classic MBPs have also been observed in spleen and lymph node macrophages (Liu et
al. 2001). On the other hand, the golli proteins result from activation of the first

20
transcription start site of the gene and while their expression in the nervous system is very
low, they are found at relatively high levels in the immune system (Pribyl et al. 1993).
As stated before, several size isoforms of classic MBP are synthesized from
differential splicing of the Golli-MBP gene (Figure 1.5). These are the 21.5, 20.2, 18.5,
17.24, 17.22 and 14 kDa species in the mouse and 21.5, 20.2, 18.5 and 17.2 kDa in
humans (Barbarese et al. 1978; de Ferra et al. 1985; Harauz et al. 2004; Kamholz et al.
1986). The 18.5 kDa isoform is the major MBP in adult human myelin, whereas the 14
kDa species is the main MBP present in adult mouse and rat myelin. All isoforms contain
protein domains encoded by exons I, III, IV and VI while only the 21.5, 20.5 and 17.22
kDa forms contain exon II. The expression and proportion of these isoforms in the CNS is
developmentally regulated. Exon II containing isoforms are expressed at high levels early
in development both in vivo and in cultures of OLGs (Barbarese et al. 1978; de Vries et al.
1997; Pedraza 1997). In contrast, the exon II lacking isoforms are the predominant MBP
proteins expressed later in myelination and in differentiated OLGs. Not only is the
expression of these isoforms developmentally regulated but different MBPs also exhibit
different locations within the cells and myelin, suggesting specific functions for each
isoform. While exon II-null isoforms were found to be confined to the plasma membrane
alone, exon II containing isoforms localized mostly within the cytoplasm and nucleus
(Allinquant et al. 1991; Staugaitis et al. 1990).
With regards to spatial expression within the CNS, in the postnatal period, the
peak of mRNA expression is not region dependent for CNP, PLP and MBP suggesting a
common signal occurring concurrently in all areas, irrespective of the caudo-rostral
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Fig 1.5: The MBP gene. (A) the amino acid sequences corresponding to the various
mouse MBPs are encoded in a gene containing at least 11 exons.The exons are depicted in
boxes with the original MBP exon numbering above and the golli MBP exon numbering
below. (B) The MBP exons can be spliced to give an mRNA containing the original seven
MBP exons (except exon 5A) which gives the 21.5 kDa MBP. Alternative MBP mRNA
splicing results in transcripts with deletions of MBP exon 2 and/or 6 which generate the
other MBP isoforms. Modified from Basic Neurochemistry, edited by Siegel, Albers,
Brady and Price, Elsevier, 2006
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gradient of myelination in the brain (Kanfer et al. 1989). Importantly, MBP expression in
the OLGs appears to be subjected to neuronal regulation as levels of these proteins are
significantly increased in co-cultures with neurons (Macklin et al. 1986).
MBP plays a crucial role in myelin compaction. This function is demonstrated in
the naturally occurring mouse mutant shiverer, in which a large part of the MBP gene is
deleted resulting in failure to synthesize MBP protein. These animals lack myelination of
the CNS although OLG processes contact and start to wrap axons. However, the mutant
phenotype can be rescued by transgenic MBP expression (Popko et al. 1987).
Furthermore, in these transgenic mice, the amount of myelin synthesized was shown to be
directly proportional to the level of MBP expression. Similarly, the Long Evans shaker rat
shows severe CNS dysmyelination that results from lack of MBP expression due to a large
insertion in the MBP gene causing aberrant MBP mRNA processing (O'Connor et al.
1999).
Thus, it is clear that MBPs are required for myelination and therefore, their
expression is subjected to regulatory mechanisms which are still poorly understood. As
described later in this thesis, we have found that NT-3 is a potent stimulator of MBP
expression in the developing OLGs. Amazingly, a mature myelinating OLG produces upto
ten times its own weight in protein to make the myelin sheath. Thus, the next section
provides a brief overview of OLG biology with special emphasis on factors controlling
their development.
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Oligodendrocytes
The study of glial cells can be traced back as early as 1846 when Virchow
described the presence of a „fragile, non-nervous, interstitial component made up of
stellate or spindle-shaped cells morphologically distinct from neurons‟. Since he believed
them to be a sort of connective tissue-like substance in which the neurons were embedded,
he named them „nervenkitt‟ or nerve putty (Virchow 1856). Years later in 1874, Boll
demarcated connective tissue from glial cells by demonstrating marked differences in both
staining properties and histogenesis (Boll 1874). However, it was the Nobel Laureate
Cajal who revolutionized the field of glial cell biology with his extensive work on
developing differential staining techniques for the various cells of the nervous system.
Cajal in his extensive treatise „Texture of the Nervous System of Man and the
Vertebrates‟ provided detailed morphological descriptions of neurons, astrocytes and a
mysterious „third element‟. An acclaimed student of Cajal, Rio Hortega decoded the
enigma of the „third element‟ in 1924 by describing the existence of microglia as well as
„glia of scarce radiations‟ or oligodendroglia in the central nervous system. Although
myelin was discovered almost a century earlier in 1878 by Louis-Antoine Ranvier, its
origin remained undiscovered until 1928 when Hortega alluded to a possible myelinforming function of OLGs. In fact, the term oligodendroglia was introduced by Rio
Hortega (Rio-Hortega 1921) to describe those neuroglial cells that show few processes
when stained by metallic impregnation techniques. The development of these specialized
staining techniques by Cajal and Rio Hortega allowed recognition of OLGs as multipolar
neuroglial cells with a range of morphological appearances. The in situ morphology of
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OLG processes was confirmed using intracellular injection of the fluorescent dye, Lucifer
yellow (Butt and Ransom 1989). In electron micrographs, OLGs are identified by their
round or oval nuclei with variably clumped chromatin and scanty, electron dense
cytoplasm. Their perikarya and processes include mitochondria and endoplasmic
reticulum, but not intermediate filaments or glycogen granules (Butt 2005; Peters et al.
1991). Conventional histochemical techniques with light and electron microscopy can
reliably distinguish OLGs from other cell types in normal tissue. Several features can
distinguish OLGs from astrocytes: their smaller size, denser cytoplasm and nucleus,
absence of intermediate filaments and of glycogen in the cytoplasm and the presence of a
high number of microtubules in their processes that may be responsible for their stability
(Lunn et al. 1997). A single OLG extends many processes, each of which makes contact
with a stretch of axon. On the same axon, adjacent myelin sheaths belong to different
OLGs. Although most OLGs contribute to the formation of myelin, there are also satellite
OLGs which may not be directly connected to the myelin sheath (Penfield 1932) and it is
believed that these cells may serve to regulate the microenvironment around neurons
(Ludwin 1997). Before they reach maturity and engage in myelin formation, OLGs go
through several stages of development (Fig 1.6). It is insufficient to characterize these
stages by morphological criteria alone both in vivo and in vitro. Therefore, a number of
distinct phenotypic stages have been identified based on the expression of various specific
components (antigenic markers) and the mitotic and migratory status of these cells. In the
mammalian brain, OLG precursors are initially found in the ventricular and subventricular
zone (SVZ) (LeVine and Goldman 1988a). From here, they subsequently migrate to other
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Figure 1.6: Stages in the development of oligodendrocytes. Each stage of OLG
differentiation is characterized by the expression of specific markers. Early progenitors
are bipolar cells that can be labeled with the A2B5 antibody and express the PDGF-α
receptor and the NG2 chondroitin sulfate proteoglycan. The next stage is represented by
committed OLGs, multipolar cells that react with both O4 and O1 antibodies. The
expression of the myelin proteins, including MBP and PLP, marks the final stage of
differentiation.
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regions of the CNS while undergoing several steps of differentiation. Early proliferative
progenitors are bipolar and express the NG2 chondroitin sulfate proteoglycan, the plateletderived growth factor alpha receptor (PDGF-α R) (Chang et al. 2000; Levine 1994;
Levine et al. 1998; Levine et al. 2001; Levine et al. 1993; Nishiyama 2001; Nishiyama et
al. 1999; Nishiyama et al. 1996a; Nishiyama et al. 1996b; Reynolds and Hardy 1997;
Trapp et al. 1997). These immature cells are labeled with the A2B5 antibody that
recognizes several gangliosides including GT3 and its O-acetylated derivative (Dubois et
al. 1990; Farrer and Quarles 1999). Both antigens are down-regulated as the OLG
progenitors differentiate into committed OLGs which are multipolar and react with both
the O4 and O1 antibodies (Sommer and Schachner 1981). The expression of the myelin
proteins, including the enzyme CNP, MBP and PLP marks the progression of the cells
into the final stage of fully differentiated OLGs (Kumar et al. 1988; McMorris et al. 1981;
Reigner et al. 1981).
The final number of mature OLGs depends on the balance between the
proliferative rate of the OLG progenitors and their death by apoptosis that occurs in the
early phases of development. This balance is highly influenced by extracellular signals in
their environments (Barres et al. 1993). Importantly, a certain proportion of OLG
progenitors remains as such in the mature CNS and moreover, these cells were shown to
be recruited to demyelinated areas in experimental demyelination and in Multiple
Sclerosis (MS) to remyelinate naked axons (Chang et al. 2000; Keirstead and Blakemore
1999). Therefore, identification and understanding of the endogenous signals promoting
OLG progenitor survival and their subsequent differentiation to myelinating cells are
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crucial to the development of remyelinating therapies. Yet, the molecular mechanisms that
control these processes in the OLG progenitors remain poorly understood.
Several lines of evidence suggest that the proliferation and differentiation of OLG
progenitors are independently controlled processes as inhibition of OLG proliferation does
not necessarily result in differentiation and each of these processes can be regulated in a
separate manner by distinct factors (Rosenberg et al. 2007). Likewise, although
differentiation and myelination represent intimately related steps in the maturation of an
OLG, studies of myelin formation in the optic nerve suggest that differentiation and
myelination can be differentially controlled (Colello et al. 1995).
The ability of the progenitors to proliferate appears to depend on both extrinsic and
intrinsic cues. In vitro studies demonstrated that one of the main inducers of OLG
progenitor proliferation is PDGF, a growth factor which is secreted by both astrocytes and
neurons (Levine 1989; Noble et al. 1988; Raff et al. 1988; Richardson et al. 1988; Yeh et
al. 1991). In addition, a significant increase in the number of OLG progenitors was
observed in transgenic mice with neurons overexpressing PDGF (Calver et al. 1998).
OLG progenitors cultured in the presence of PDGF will divide indefinitely (Barres et al.
1994a; Durand et al. 1998). However, the co-addition of factors regulating cell cycle
arrest can stop this PDGF-induced proliferation. For example, the addition of factors such
as thyroid hormone (TH) and retinoic acid (RA) limits the proliferative capacity of
cultured OLG progenitors (Barres et al. 1994a; Gao et al. 1997). In fact, in the presence of
both PDGF and TH, OLG progenitors experience a fixed period of cell division, followed
by differentiation. Under these conditions, the transition from progenitor cell to mature
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OLG appears to be regulated by an intrinsic program (Raff 2006). In this regard, several
studies suggest that an internal „clock‟ may be responsible for monitoring the amount of
time an OLG progenitor spends proliferating and for initiating cell cycle arrest at the
appropriate time (Gao et al. 1997). The possibility of this intrinsic mechanism regulating
OLG progenitor division was originally suggested by experiments in which single OLG
progenitors, isolated from postnatal day 1 and 7 rat optic nerves, were individually plated
onto monolayers of purified astrocytes (Temple and Raff 1986). In these experiments, the
majority of OLG progenitors having the same clonal origin divided a fixed number of
times before undergoing differentiation at similar times. These results suggests the
involvement of a specific intrinsic mechanism that is responsible for regulating the timing
between the end of proliferation and the start of differentation. Although the number of
divisions varied between clones, the majority of progenitors exhibited a cell cycle time of
1-2 days (Temple and Raff 1986). These findings provide compelling evidence that
variability can exist within a given population of purified OLG progenitors. It was also
demonstrated that differentiation occurs in a graded fashion, evidenced from studies in the
optic nerve (Colello et al. 1995). In support of the potential intrinsic timer mentioned
above, elegant studies using OLG progenitors cultured on monolayers of type 1 astrocytes
(Temple and Raff 1986) showed that sister cells from the same clone recultured separately
in isolated environments behaved almost identically with regards to rates of cell division
and differentiation (Temple and Raff 1986). These in vitro studies further suggest the
existence of an intrinsic mechanism that ensures the synchronized differentiation of
related OLG progenitors. Subsequent research has provided additional insight into the role
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of this intrinsic regulatory mechanism in OLG differentiation. The intracellular timing
mechanism functions when OLGs are actively dividing, as in the presence of PDGF.
However, in the absence of PDGF and TH, over 98% of cultured OLG progenitors fail to
divide extensively and will differentiate into mature OLGs within 48 hours (Barres et al.
1994a; Noble and Murray 1984; Temple and Raff 1985). This, it appears that the intrinsic
timer is indeed responsible for determining when proliferation is sufficient and enough
new cells have been generated. At this point, TH can intervene to stop proliferation and
allow differentiation (Barres et al. 1994a). Interestingly, the cell cycle inhibitor p27

Kip1

has also been shown to be involved in the intrinsic mechanism to regulate proliferation.
Normal progression through the cell cycle is modulated by interactions between cyclins
and cyclin-dependent kinases (cdks). The formation of cyclin-cdk complexes such as the
cyclin E-cdk2 complex activates signaling cascades that promote cell division. Formation
of this particular complex is regulated by p27

Kip1

. Overexpression of p27

Kip1

in OLG

progenitors in vitro arrests the cell cycle by inhibiting cdk2 activity (Tang et al. 1999).
Interestingly, earlier studies showed that OLG progenitors actively proliferating in the
presence of PDGF exhibited a gradual increase in p27 Kip1 expression (Durand et al. 1997).
In the absence of PDGF, when OLG progenitors differentiate within 48 hours, the rate at
which p27

Kip1

expression increases is significantly increased correlating with withdrawal

from the cell cycle (Casaccia-Bonnefil et al. 1997; Durand et al. 1998; Tang et al. 1998).
Not only does p27

Kip1

expression increase in the presence of mitogens but can also

depend on the environmental temperature of the OLG cultures (Gao et al. 1997). In fact,
OLG progenitors cultured at 33 0C divide more slowly but differentiate after fewer
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0

divisions than cells cultured at 37 C (Gao et al. 1997). However, merely inhibiting
proliferation does not result in induction of differentiation. In addition to the specific cellintrinsic mechanisms described above, growth factors also strongly influencel the decision
of the cell to differentiate. In fact, OLGs at all stages of development require continuous
signaling by protein trophic factors to avoid programmed cell death in culture (Barres et
al. 1993). Three classes of such trophic factors promote OLG survival in vitro: (1) insulin
and insulin-like growth factors (IGFs), (2) neurotrophins, particularly neurotrophin-3 (NT3), and (3) ciliary-neurotrophic factor (CNTF), leukemia inhibitory factor (LIF) and
interleukin 6 (IL-6). A single factor, or combinations of factors within the same class, can
promote only short-term survival of OLGs, while combinations of factors from different
classes promote survival additively. Long-term survival of OLGs in vitro requires at least
one factor from each class. Among the neurotrophins, NT -3, in particular has been shown
to be very important in the development of OLGs.

Role of NT-3 in oligodendrocyte development
NT-3 belongs to the family of neurotrophins, a group of six highly homologous
peptides which, in addition, include nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), NT-4/5, NT-6 and NT-7 (Barbacid 1995; Fagan et al. 1996;
Gotz et al. 1994; Nilsson et al. 1998). Neurotrophin effects are mediated by the
tropomyosin-related tyrosine protein kinase (Trk) family of receptors that includes TrkA,
TrkB, and TrkC. NGF specifically recognizes TrkA, a receptor identified in all major
NGF targets, including sympathetic, trigeminal, and dorsal root ganglia as well as in
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cholinergic neurons of the basal forebrain and the striatum. BDNF and NT-4 specifically
activate the TrkB tyrosine kinase receptor. NT-3 primarily activates the TrkC tyrosine
protein kinases, four related isoforms encoded by alternative splicing of trkC, a gene also
widely expressed throughout the mammalian nervous system. Unlike the other
neurotrophins, NT-3 appears to be somewhat non-specific since not only activates TrkC
but it can also bind, although to a lesser extent and in certain cell systems, to the TrkB
kinase receptor (Barbacid 1994). In addition to their binding to the high affinity Trk
family of receptors, all neurotrophins have the capacity to interact with the low affinity
neurotrophin receptor p75.
Developing OLGs express the NT-3 receptor TrkC (Cohen et al. 1996; Heinrich et
al. 1999; Kahn et al. 1999; Kumar and de Vellis 1996) and its importance in these cells is
supported by the fact that examination of NT-3 and TrkC knockout mice revealed a
reduction in both OLG progenitors and mature OLG numbers (Kahn et al. 1999). These
animals also exhibited deficiencies in other CNS glial cells, including astrocytes and
microglia as well as reduced size of the SVZ, a region which as indicated before generates
highly proliferative glial progenitors (Kahn et al. 1999).
Interestingly, studies in cultured cells demonstrated that TrkC levels in OLGs are
developmentally regulated, exhibiting a substantial decrease in the mature cells
(Kavanaugh et al. 2000). Results from different laboratories have shown that NT-3
induces survival and proliferation of OLG progenitors both in vitro and in vivo (Barres et
al. 1994b; Barres et al. 1993; Bertollini et al. 1997; Johnson et al. 2000; Kumar et al.
1998; Robinson and Miller 1996; Wilson et al. 2003). Additionally,

experiments in
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cultured cells suggested that NT-3 and PDGF collaborate to promote clonal expansion of
OLG progenitors and to drive the intrinsic clock that times OLG development (Barres et
al. 1994b). In vivo results showed an increased expression of the progenitor cell marker,
glycerol phosphate dehydrogenase (GAPDH) within 48 hr following an intracranial
injection of NT-3, PDGF or both in post-natal day 4-5 rats. These findings showed that
NT-3 could augment the activity of PDGF potentiating the ability of the OLG progenitors
to enter into the S-phase of the cell cycle (Kumar et al. 1998). The proliferative effect of
NT-3 on OLG progenitors appears to be spatially regulated as NT-3 was found to enhance
the PDGF-induced proliferation of these cells in the optic nerve while having a negligible
effect in the case of the spinal cord progenitors (Robinson and Miller 1996). Importantly,
similar to its effects on the rodent cells, NT-3 was also found to stimulate the proliferation
of cultured fetal human OLG progenitors (Wilson et al. 2003), results that further
reinforced the role for NT-3 in OLG lineage development.
As indicated above, results from different laboratories showed that NT -3 not only
stimulates the proliferation of OLG progenitors but also their survival (Barres et al.
1994b; Barres et al. 1993; Bertollini et al. 1997; Coelho et al. 2007; Johnson et al. 2000;
Kahn et al. 1999; Kumar et al. 1998; Robinson and Miller 1996; Wilson et al. 2003).
Importantly, NT-3 has been shown to diminish the susceptibility of cultured OLGs to
glutamate induced excitotoxicity (Kavanaugh et al. 2000). This anti-excitotoxic effect of
NT-3 was Trk-mediated and was independent of a decrease in the amplitude of the early
rise in intracellular calcium which was induced by activation of the glutamate receptor
(Kavanaugh et al. 2000).
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Studies investigating the signaling mechanisms underlying NT -3 action in OLG
progenitors showed that this neurotrophin causes activation of p21ras and extracellular
signal-regulated protein kinase 1/2 (ERK1/2) (Kumar et al. 1998). Previous results from
our laboratory indicated that treatment of OLG progenitors with NT-3 results in
phosphorylation and activation of the transcription factor CREB (cyclic-AMP response
element binding protein) (Johnson et al. 2000). This NT-3-induced activation of CREB
involved the concerted action of both the ERK and PKC dependent pathways (Johnson et
al. 2000). Moreover, experiments in which CREB expression was downregulated with a
specific antisense probe demonstrated that this transcription factor plays a crucial role in
the mechanism by which NT-3 stimulates OLG proliferation (Johnson 2000). Studies
from Saini et al. (2004) showed that treatment of OLG progenitors with NT-3 is also
accompanied by an increase in the levels of the anti-apoptotic protein Bcl-2. Because the
Bcl-2 gene promoter has a putative CREB binding site (CRE), the previous observation
raised the possibility that CREB could also play a function in modulating Bcl-2
expression in the OLGs. In support of this possibility, those studies also showed that the
NT-3 dependent increase in Bcl-2 levels was abolished by inhibition of CREB expression.
Additionally, experiments transfecting the OLG progenitors with luciferase reporter
constructs containing various regions of the Bcl-2 promoter and mutation of the CRE site
indicated a direct role of CREB in regulating Bcl-2 gene activity in response to NT-3.
Furthermore, protein-DNA interaction studies demonstrated that the CREB protein from
freshly isolated OLGs indeed binds to the Bcl-2 promoter CRE. Altogether, these
observations suggested that CREB plays an important role linking proliferation and
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survival pathways in the OLG progenitors in response to NT-3 stimulation (Saini et al.
2004).
Interestingly, we found that CREB phosphorylation in response to NT-3
stimulation also involved the enzyme sphingosine kinase 1 (SphK1) (Saini et al. 2005).
This enzyme catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate
(S1P), a potent bioactive lipid that regulates multiple biological processes including cell
proliferation, survival, motility and migration (Spiegel et al. 2002; Watterson et al. 2005).
Furthermore, our results showed that S1P, by itself, can mediate the phosphorylation of
CREB in the OLGs (Saini et al. 2005). Previous studies showed a role for S1P as a
mediator of NGF action in PC12 cells and hippocampal and DRG neurons (Culmsee et al.
2002; Edsall et al. 1997; Rius et al. 1997; Toman et al. 2004). Confocal analysis of the
OLG progenitors demonstrated that treatment of these cells with NT -3 resulted in
intracellular translocation of SphK1 to the plasma membrane and importantly, siRNA
experiments showed that SphK1 was required for NT-3 to stimulate OLG progenitor
survival (Saini et al. 2005). Altogether, these findings demonstrated for the first time, the
presence of a cross-talk mechanism between NT-3 signaling and sphingolipid metabolism.
A proposed mechanism for this interaction is shown in Figure 1.7.
The discovery of an interaction between NT-3, SphK1 and S1P signaling was
particularly relevant in view of reports indicating that FTY720, an immunosuppressant
drug which is an analog of sphingosine, protects animals against experimental
autoimmune encephalomyelitis (EAE) (Fujino et al. 2003; Rausch et al. 2004; Webb et al.
2004) , an experimental animal model of MS.

Thus,

following

our

previous
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observations, the studies in Chapter 2 of this thesis were focused on investigating potential
direct actions of FTY720 and interaction of this drug with NT-3 signaling in OLG
progenitors (Coelho et al. 2007).
Besides the roles of NT-3 in regulating OLG survival and proliferation described
above, several lines of evidence also suggest that this neurotrophin plays a crucial
function modulating OLG maturation. In studies aimed at analyzing the effects of
neurotrophins on basal forebrain and cortical OLGs, it was found that NT-3 treatment
increased the expression of MBP and enhanced the population of MBP positive cells,
without affecting total cell numbers (Du et al. 2003). Additionally, an increase in process
formation and arborization was observed in GalC positive OLGs that resulted from
cultures of OLG progenitors treated for 8-24 hours with NT-3 (Heinrich et al. 1999) and
western blot analysis showed that OLG progenitors transfected with the NT-3 gene in
vitro were able to enhance expression of MBP nearly 10-fold (Rubio et al. 2004).
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Figure 1.7: Proposed mechanism of NT-3-dependent CREB phosphorylation in OLG
progenitors. Upon NT-3 binding, TrkC receptor subunits autophosphorylate and initiate a
signaling cascade that results in CREB activation through the concerted action of
ERK1/2-

and

PKC-dependent

pathways. This

cascade

involves

a

traditional

MEK/ERK1/2 pathway as well as translocation of SphK1 to the plasma membrane of the
cells, resulting in S1P synthesis. S1P may act as an autocrine factor that binds to S1P
receptors, further stimulating CREB phosphorylation by means of ERK and PKC
activities.
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Moreover, in DRG neuron-OLG co-cultures, treatment with NT-3 significantly increased
the number of myelinated axons pointing towards a differentiation-enhancing role of NT-3
in OLGs (Yan and Wood 2000). Furthermore, NT-3 was able to induce a dramatic
increase in MBP positive cells detected by immunohistochemistry in animal models of
chemical demyelination (Jean et al. 2003) and in spinal cord injury (McTigue et al. 1998).
These in vivo studies are particularly important because they suggest that NT-3 may play
an important role regulating OLG number and myelin regeneration following CNS injury
and demyelination.
However, the molecular mechanisms responsible for NT-3 action in OLG
maturation are poorly understood. Chapter 3 describes our most recent studies
demonstrating a novel mechanism by which NT-3 plays a role in OLG development by
engaging the translation initiation cascade leading to protein synthesis. Our interest in the
capacity of NT-3 to induce differentiation of the OLG progenitors stems from the need to
identify signaling mechanisms that could be manipulated as maturation-enhancing tools.
These tools would consequently allow successful remyelination in demyelinating diseases,
particularly MS. The next section will focus on the relevant features and therapies of the
disease with regards to OLGs and remyelination.

Multiple Sclerosis
Jean Martin Charcot (1825-1893) can be accredited with the first serious study of
human demyelinating diseases, work mainly carried out in Paris's Salpêtrière Hospital in
the late 19th century. Within just a few years of observing patients with symptoms of
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demyelination, Charcot effectively gathered together descriptions of the characteristic
features and added his own clinical and pathological observations. These early accounts of
Multiple Sclerosis (MS) by Charcot were so detailed and accurate that in 1877, Julius
Althaus named the disease after him. More importantly, Charcot realized the role of
disrupted myelin in the pathogenesis of the disease. He, however, was mistaken in his
pathophysiological explanation of the demyelination, speculating that it was caused by
overgrowth of glia and subsequent „strangulation‟ of the myelin sheath. Work by several
eminent scientists encompassing centuries of meticulous research has brought us to the
current understanding that MS is indeed a chronic inflammatory disease of the CNS,
characterized by demyelination and death of OLGs (McQualter and Bernard 2007).
Epidemiologically, this disease affects young adults and often follows a highly variable
pattern. The disease begins in the third or fourth decade of life and the initial course is
characterized by acute episodes of neurological dysfunction followed by subsequent
recovery. This pattern is known as relapsing-remitting MS. Over time, there may be
incomplete recovery after attacks and this signifies the progression of the disease into one
of increasing disability, termed secondary progressive MS. A small percentage of patients
will have a very aggressive course, which may even terminate in death. In order to
establish a diagnosis of MS, there must be evidence to show the involvement of two areas
of the CNS and clinical history to determine that this involvement occurred at two
different times and without any other identifiable cause. Although the exact etiology of
the disease remains elusive, the concept that the immune system plays a central role in the
pathogenesis of MS is indisputable since the pathological hallmark of MS is the presence
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of focal areas of inflammatory-mediated demyelination of the brain and spinal cord.
Another factor in favor of an immune-mediated pathology is the observation that
increased susceptibility to MS is genetically linked with the immune molecule, major
histocompatibility complex (MHC) class II, although linkage studies have attributed only
a 3% increased risk of MS within families of identified patients. Regardless of the origin
and in view of all the evidence supporting an autoimmune component, the general theory
of MS etiology assumes that this is a disease in which the immune system is presented
with an antigen similar to a CNS myelin molecule. This triggers an autoimmune attack on
existing normal myelin and OLGs, resulting in demyelination. This concept has been
reinforced by experimental animal models in which immunization with myelin, myelin
proteins or peptides induced immune-mediated destruction of CNS myelin. However, this
theory is not wholly acceptable as MS can cover several etiologically distinct diseases
with similar clinical features and pathological endpoints. MS can present as a number of
different demyelinating patterns covering a spectrum of pathological features. One such
presentation involves primary demyelination with little OLG loss while another includes
extensive OLG loss during the course of demyelination. Alternatively, there may be
primary OLG loss with secondary demyelination. Axonal loss is also a prominent feature
of MS and maybe viewed as the pathological correlate of the irreversible neurological
impairment in this disease (Trapp and Nave 2008). Since MS involves both an immune
attack resulting in loss of myelin and OLGs, treatment for the disease must have a dual
purpose: to halt the immune destruction and to remyelinate the sclerosed areas of the brain
and spinal cord. Interestingly, demyelination in the CNS may be naturally followed by
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spontaneous remyelination. This has been described in a number of experimental models
as well as in naturally occurring demyelinating disease, most notably in acute lesions of
MS. Several lines of evidence demonstrate that remyelination is an important contributor
to recovery of functional deficits that arise due to demyelination (Jeffery and Blakemore
1997). The occurrence of remyelination in MS was initially suggested by Marburg who
identified thinly myelinated axons at the edge of lesions and inferred that they might
represent a regenerative response (Marburg 1906). There is now clear evidence to show
that remyelination can occur in MS lesions and this can occur extensively within a lesion
(Prineas et al. 1993; Prineas and Connell 1979; Prineas et al. 1989; Raine and Wu 1993).
When an area of white matter has been remyelinated, the number of OLGs in that area is
greater than it was before demyelination (Prayoonwiwat and Rodriguez 1993) suggesting
that there must be some mechanism by which new OLGs are generated. Although OLGs
may be able to survive within an area of demyelination, two lines of evidence indicate that
it is unlikely that they are able to regenerate new myelin sheaths and contribute to
remyelination. First, GalC expressing OLGs isolated from adult white matter do not form
new myelin sheaths when transplanted into areas of demyelination (Franklin 2002; Targett
et al. 1996). Secondly, post mitotic OLGs that survive a demyelinating episode in spite of
losing their myelin sheaths do not contribute to subsequent remyelination (Franklin 2002;
Keirstead and Blakemore 1997). These findings suggest that demyelination may induce
the production of new OLGs. However, the source of these newly generated cells
constitutes one of the long-standing mysteries of remyelination research. Several groups
have shown that most of the cells that contribute to remyelination come from OLG
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progenitors (Blakemore and Keirstead 1999; Ludwin and Bakker 1988; Mason et al. 2000;
Wood and Bunge 1991). The evidence for this is based on the following observations:
first, proliferating cells that are likely to be OLG progenitors and can be labeled either by
injecting a LacZ-expressing retrovirus into normal adult white matter or by labeling with
tritiated thymidine or BrdU give rise to labeled remyelinating OLGs following induction
of demyelination (Carroll and Jennings 1994; Gensert and Goldman 1997; Watanabe et al.
2002). The second line of evidence shows that OLG progenitors isolated from adult CNS
can remyelinate areas of demyelination following transplantation (Windrem et al. 2002;
Zhang et al. 1999). Third, the OLG progenitors identified with a range of markers that
include PDGFαR (Redwine and Armstrong 1998; Sim et al. 2002), the proteoglycan NG2
(Di Bello et al. 1999; Levine and Reynolds 1999) and the zinc finger transcription factor
(Sim et al. 2002) have patterns of expression that are consistent with being the source of
new OLGs. Progenitor cells at even earlier stages in the OLG lineage are also likely to
contribute to the generation of mature cells capable of remyelination because cells are
recruited from the SVZ where these early progenitors are found when demyelination
occurs in the vicinity (Nait-Oumesmar et al. 2007). A further level of complexity, as
shown by studies with tissue culture, has been discovered with the finding that the OLG
progenitor population is heterogenous (Gensert and Goldman 2001). If such heterogeneity
exists in vivo, then the possibility exists that different types of progenitors respond to
environmental cues or contribute to remyelination in different ways (Mason and Goldman
2002). Remyelination involves several stages. The first important step is to populate an
area of demyelination with sufficient OLG progenitors. These can come from cells
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existing within the demyelinated region or they might be recruited from neighboring intact
brain tissue. This initial recruitment phase involves OLG progenitor proliferation and
migration. After they reach the area of demyelination, the OLG progenitors must
differentiate into myelinating OLGs. During this maturation phase, the OLG progenitors
progressively develop into premyelinating OLGs that engage the axon before finally
becoming mature OLGs that form the spiral wraps of membrane. The renewed myelin
sheath is generally thinner and shorter than the original sheath. However, it retains the
composition and is subject to the same transcriptional regulation as in developmental
myelination (Morell et al. 1998; Sim et al. 2000). Despite increasing understanding of the
biology of remyelination, there is no clear picture as yet of why this process fails along the
course of MS and other demyelinating diseases (Franklin 2002). There may be many
different reasons. Remyelination may fail because of an inadequate recruitment of OLG
progenitors or because of failure of the OLG progenitors to differentiate into myelinating
OLGs. Both of these phases of remyelination become more prolonged with increased age,
leading to a decrease in remyelination efficiency (Franklin et al. 2002; Rist and Franklin
2008). In addition, remyelination will not occur if axons are lost which takes place in
demyelinating disorders. However, even the presence of axons may not be enough if these
axons do not relay differentiation signals to the OLG progenitors or if they express
molecules that inhibit myelin sheath formation. Several studies have shown that some
chronically demyelinated lesions are not deficient in OLG progenitors. In these cases,
remyelination failure is not due to a scarcity of OLG progenitors but rather with their
failure to differentiate into mature OLGs (Chang et al. 2000; Maeda et al. 2001; Scolding

46
et al. 1998; Wolswijk 1998a). One approach to solve this problem would be to enhance
differentiation of the OLG progenitors by adding growth factors that can stimulate their
maturation. The prospect that growth factors may provide a means of promoting
remyelination by stimulating OLG progenitor differentiation has been researched
thoroughly (McMorris and McKinnon 1996; Wolswijk 1998b; Woodruff and Franklin
1997). Although much remains to be learned about the exact roles of growth factors in
remyelination, it has become clear from the existing experimental data that the process
requires the sequential expression of different growth factor combinations. At present
there are no therapies that specifically aim to enhance remyelination. So far,
immunosuppressive therapies have proven to be effective in slowing the progression of
MS. Thus, most therapeutic approaches involve the use of anti-inflammatory drugs and
immunosuppressants such as interferon-β and glatiramer acetate. Recently much attention
has been given to a new immunosuppressant, FTY720 or Fingolimod that acts by
counteracting the immune-specific functions of the bioactive lysosphingolipid S1P, the
phosphorylated form of sphingosine. The next section will review current knowledge
about the actions of S1P and FTY720 on the CNS.

FTY720
FTY720

(2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol)

was

developed

by

chemical modification of ISP-1 (myriocin), a lipid metabolite produced by the Isaria
Sinclarii, a fungus that has been used in traditional Chinese medicine for hundreds of
years. S1P, an important bioactive lipid, is produced by cells of the innate immune system
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(mast cells, macrophages, and granulocytes) (Goetzl and Rosen 2004) and by endothelial
cells, neurons and astrocytes in the CNS (Anelli et al. 2005; Bassi et al. 2006; Kajimoto et
al. 2007; Singleton et al. 2007) in micromolar concentrations (Pappu et al. 2007). S1P can
act in an autocrine or paracrine fashion on immune and neural cells through the S1P G protein coupled receptors (GPCRs). There are 5 known S1P GPCR isoforms that belong
to the endothelial differentiation gene-related (EDG) receptor family. Interestingly,
mRNA levels of EDG-2 receptor was found to be upregulated in the periphery of MS
lesions (Beer et al. 2000). Furthermore, it has been shown that activity of the enzyme that
synthesizes S1P, sphingosine kinase, is increased in ischemia (Blondeau et al. 2007).
Also, S1P levels were seen to be raised in the injured spinal cord (Kimura et al. 2007) and
in inflammatory conditions (Mechtcheriakova et al. 2007).
Since FTY720 is an analog of sphingosine (Fig 1.8A), the phosphorylated form of
the drug is an agonist at the S1P receptors. FTY720 is rapidly phosphorylated to its
biologically active form in vivo (Billich et al. 2003; Brinkmann et al. 2002; Zemann et al.
2006) and in vitro (Paugh et al. 2003) by the sphingosine kinases (Fig 1.8B). Once
phosphorylated, it can then act on S1P1, 3, 4 and 5 (Brinkmann et al. 2002). The binding
of FTY720 to these receptors, particularly S1P1, has been shown to result in
internalization to late endosomal vesicles (Gonzalez-Cabrera et al. 2007), degradation (Jo
et al. 2005) and ubiquitination and proteosomal degradation (Oo et al. 2007).
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Fig 1.8: Structure of FTY720 (A) FTY720 is a structural analog of sphingosine (B) S1P
is generated via the intracellular ceramide (Cer) pathway, where Cer is formed through de
novo biosynthesis or degradation of the cell membrane constituent sphingomyelin (SM).
Cer is N-deacetylated to yield sphingosine, and both sphingosine and FTY720 are
phosphorylated by sphingosine kinases to form S1P and FTY720-P, respectively.
FTY720-P is the biologically active metabolite of the drug. Modified from Brinkmann et
al, Am J Transplant, 2004.
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In order to determine potential blood-brain-barrier (BBB) responses to these lipids,
several studies have investigated the effects of S1P and FTY720 on endothelial cells.
Exposure of human pulmonary endothelial cells to S1P reduces permeability of the lung
vasculature through activation of S1P1 and Rac1 GTPase-mediated actin cytoskeleton
rearrangement (Singleton et al. 2006). Experiments testing the effect of FTY720 on the
integrity of the endothelial cell barrier showed similar decreases in permeability of the
pulmonary vasculature (Dudek et al. 2007). However, the FTY720-induced effects were
not mediated through S1P1 (Dudek et al. 2007). These positive effects of FTY720 and
S1P on the endothelial barrier function suggest that a similar action may potentially be
observed at the level of the BBB. Furthermore, treatment of human umbilical vein
endothelial cells with FTY720-P led to a robust increase in calcium mobilization (Butler
et al. 2004). In vascular endothelial cells, FTY720-P induces translocation of cadherin and
β-catenin to the focal contact sites between the cells, thereby promoting adherens junction
assembly (Brinkmann et al. 2004; Lee et al. 2006). The comparable effects of S1P and
FTY720 treatment of mice on BBB permeability has lead to a debate on whether S1P
receptors are truly internalized by FTY720 (Brinkmann et al. 2004). It would seem logical
to assume that the endothelial cells of the BBB could continuously respond to FTY720induced increases in barrier permeability and contribute to clinical outcome. In vivo
studies take advantage of the ability of orally administered FTY720 to cross the BBB and
access the CNS (Sanchez and Hla 2004). Since neural cells possess endogenous SphK
activity, this can contribute to the phosphorylation of the drug to FTY720-P (Billich et al.
2003; Meno-Tetang et al. 2006b). In experiments to determine the levels of both FTY720
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and its phosphorylated forms in the rodent CNS, it was found that both molecules reached
a higher concentration in the brain parenchyma as compared to the blood. While blood
levels remained constant over a period of 21 days, brain concentrations continued to
increase over time (Foster et al. 2007). Interestingly, light microscopy of [14C]FTY720
labeling in the brains of these rats showed colocalization with myelin suggesting that a
major portion of the drug is incorporated into myelin (Foster et al. 2007).
Importantly, several other studies have evaluated the effect of FTY720 on acute
experimental autoimmune encephalomyelitis (EAE), an animal model for MS. Treatment
with FTY720 was shown to ameliorate EAE symptoms in both rats and mice (Foster et al.
2008; Fujino et al. 2003; Kataoka et al. 2005; Rausch et al. 2004; Webb et al. 2004) and to
be accompanied by inhibition of T cell infiltration (Brinkmann and Lynch 2002; Fujino et
al. 2003; Kataoka et al. 2005) and reduced expression of pro-inflammatory (IL-6) and
inflammatory (IL-2 and IFN-γ) cytokines (Foster et al. 2008; Fujino et al. 2003).
Importantly, in recent experiments to test the efficacy of FTY720 oral monotherapy in
EAE rats, it was found that even at prophylactic doses, FTY720 was able to prevent
evoked potential and other electrophysiological disturbances in the diseased rats (Balatoni
et al. 2007). Furthermore, treatment with FTY720 at therapeutic doses restored neuronal
function in fully-established EAE (Balatoni et al. 2007). Randomized clinical trials of the
drug have yielded promising results showing a significant reduction of both demyelinating
lesions and clinical disease activity in patients treated with FTY720, further supporting
the potential use of this drug for the treatment of relapsing MS (Kappos et al. 2006).
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There has been no evident effect on resident CNS cells per se in the EAE models.
However, there have been several well-documented reports of FTY720 actions on neural
cells in culture. The concentration of FTY720 used in these in vitro studies falls in the
range of 10 nM to 10 µM, which is well within physiological limits achieved in the brain
after oral and intravenous administration of the drug (Meno-Tetang et al. 2006b). In vitro
studies to compare the effects of FTY720 on thymocytes and neurons showed that
although the drug induced apoptosis in both types of cells at a concentration of 10 µM, the
effect was significantly higher in thymocytes (Oyama et al. 1998). However, as the
concentration of the drug was increased to 30 µM, the cytotoxicity on neurons became
dramatically higher (Oyama et al. 1998). Pure astrocyte cultures were shown to express
S1P1 and S1P3 receptors and it was demonstrated that FTY720-P activates Gi proteinmediated signaling cascades (Mullershausen et al. 2007). Furthermore, FTY720-P
stimulated astrocyte migration (Mullershausen et al. 2007). A more detailed study into this
effect revealed that FTY720-P stimulated ERK phosphorylation in highly enriched
astrocyte cultures (Osinde et al. 2007). Selective S1P1 receptor agonists reproduced the
effects of FTY720-P while S1P1 receptor antagonists blocked them, demonstrating that
S1P1 was involved in mediating the action of FTY720-P in astrocytes (Osinde et al.
2007). Since astrocytes are thought to be major contributors to the glial scar encountered
in CNS damage, these findings have implications for repair processes in MS patients
As described before, we found that SphK1/S1P signaling plays a crucial role in the
mechanisms by which NT-3 stimulates the survival of OLGs progenitors (Saini 2005).
This finding therefore raised the possibility that FTY720 could also have a direct effect on
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OLGs. As indicated in Chapter 2, our results showed that this drug promotes the survival
of OLG progenitors (Coelho et al. 2007). This is particularly important since
replenishment of these cells has proven to be a crucial factor in determining remyelination
success. As described above, these cells are present in the adult CNS and can be
stimulated to mature to myelinating cells during conditions of demyelination. Therefore,
the factors that contribute to their survival, proliferation and differentiation must be
thoroughly researched in order to develop specifically targeted therapeutic approaches to
MS.

CHAPTER 2
THE IMMUNOMODULATOR FTY720 HAS A DIRECT CYTOPROTECTIVE
EFFECT ON OLIGODENDROCYTE PROGENITORS

ABSTRACT

The immunomodulator FTY720 has promising therapeutic effects in multiple sclerosis
(MS), a degenerative disease in which demyelination of the central nervous system (CNS)
is accompanied by death of oligodendrocytes (OLGs), the myelin producing cells. In vivo
phosphorylation of FTY720 generates an agonist for G protein-coupled receptors for
sphingosine-1-phosphate (S1P), a lipid mediator that plays a crucial role in the stimulation
of OLG survival by neurotrophin-3 (NT-3). The mechanisms underlying the action of
FTY720 in MS are not clearly understood, although the effects of this drug in autoimmune
diseases are thought to stem from its ability to reduce lymphocyte infiltration and
inflammation. Interestingly, we now found that FTY720 also has a direct effect on OLG
progenitors. Treatment of these cells with FTY720 causes activation of ERK1/2 and Akt,
accompanied by protection from apoptosis.

However, FTY720 also arrested OLG

differentiation. Importantly, this effect was counteracted by NT-3 which not only enhanced
the survival of OLG progenitors induced by FTY720 but also stimulated their maturation.
Altogether, these observations suggest that in addition to its immunosuppressive functions,
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FTY720 could also have a beneficial effect in MS by direct action on OLG progenitors.
However, the finding that FTY720 blocks the differentiation of these cells raises the
question of whether MS therapies with FTY720 should include the use of differentiationenhancing factors like NT-3. This approach would ensure both protection of existing OLG
progenitor pools against immune-mediated insults as well as stimulation of remyelination
by enhancing the maturation of these cells.

INTRODUCTION

Multiple Sclerosis (MS) is a chronic degenerative and debilitating disease of the central
nervous system (CNS) characterized by inflammation and demyelination (McQualter and
Bernard 2007).

The pathological hallmarks of MS also include axonal degeneration

(Trapp et al. 1999) and death of oligodendrocytes (OLG) (Barnett and Prineas 2004;
Lucchinetti et al. 2004), the cells that make the myelin membrane in the CNS. Although
the cause of MS remains unknown, the presence of serum antibodies against different
myelin constituents and the existence of multiple inflammatory foci in brain and spinal
cord support the idea of a predominant autoimmune component.
therapeutic

approaches

involve

the

use

of

For this reason, most

anti-inflammatory

drugs

and

immunosuppressants.
FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol), also known as
Fingolimod, is among the latest immunomodulatory agents under evaluation for the
treatment of MS. This synthetic drug was developed by chemical modification of ISP-I
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(myriocin), a sphingosine-like metabolite produced by the fungus Isaria sinclairii.
FTY720 has been shown to prolong allograft survival in different animal models of
transplantation (Chiba et al. 1996) as well as to exert a protective effect in animal models
of autoimmune diseases (Maki et al. 2002; Mizushima et al. 2004). Importantly, several
studies have evaluated the effect of FTY720 on acute experimental autoimmune
encephalomyelitis (EAE), an animal model for MS. Treatment with FTY720 was shown to
ameliorate EAE symptoms in both rats and mice (Fujino et al. 2003; Kataoka et al. 2005;
Webb et al. 2004) and to be accompanied by inhibition of T cell infiltration (Brinkmann
and Lynch 2002; Fujino et al. 2003; Kataoka et al. 2005) and reduced expression of proinflammatory (IL-6) and inflammatory (IL-2 and IFN-γ) cytokines (Fujino et al. 2003).
Moreover, recent results from a randomized clinical trial showed a significant reduction of
both demyelinating lesions and clinical disease activity in patients treated with FTY720,
further supporting the promising use of this drug for the treatment of relapsing MS
(Kappos et al. 2006). The positive action of FTY720 in EAE and MS has been attributed
to its capacity to sequester circulating lymphocytes, especially T cells, into the secondary
lymphoid tissues such as lymph nodes and Peyers‟s patches (Brinkmann and Lynch 2002;
Mandala et al. 2002). However, several lines of evidence suggest that FTY720 may also
exert additional immunomodulatory effects by interfering with dendritic cell function (Lan
et al. 2005; Muller et al. 2005) and by inhibiting cytosolic phospholipase A2 and the
production of eicosanoid inflammatory mediators in mast cells (Payne et al. 2006). Results
from different laboratories have shown that FTY720 is phosphorylated by sphingosine
kinase type 2 (SphK2) (Zemann et al. 2006) generating FTY720-phosphate (FTY720-P).
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FTY720-P is structurally similar to sphingosine-1-phosphate (S1P), a lipid metabolite
which has emerged in recent years as a potent mediator in numerous biological processes
(Herr and Chun 2007). Because of its similarity to S1P, FTY720-P is able to bind to all of
the high affinity S1P receptors except S1P2 (Brinkmann and Lynch 2002). We have
previously found that S1P signaling plays a crucial role as a mediator in the stimulation of
OLG progenitor survival by neurotrophin-3 (NT-3) (Saini et al. 2005). This observation
led us to hypothesize that FTY720 could, like S1P, have a direct effect on the OLG
progenitors. This possibility is particularly attractive as several lines of evidence indicate
that these immature cells are crucial for the replenishment of lost OLG populations and
remyelination in MS (Zhao et al. 2005). In the present study, we have found that treatment
of OLG progenitors with FTY720 results in rapid phosphorylation of ERK1/2 and Akt,
two enzymes involved in cell survival pathways. Moreover, FTY720 protects the cells
from apoptotic cell death induced by growth factor deprivation, cytokines and microglial
activation. Interestingly, FTY720 appears to inhibit the differentiation of the OLG
progenitors, a phenomenon that is counteracted by NT-3. Taken together, these
observations suggest that the beneficial effect of FTY720 in EAE and MS may not only
result from its immunomodulatory properties but may also involve a direct effect on the
OLGs. These actions may be further enhanced by combined therapies with NT-3.
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MATERIALS and METHODS

Materials: Percoll and lipopolysaccharide (LPS) were purchased from Sigma (St Louis,
MO). Reduced growth factor Matrigel was from Becton Dickinson (Franklin Lakes, NJ).
FTY720 was obtained from Cayman Chemicals (Ann Arbor, MI). The active enantiomer
of FTY720-P, (S)-FTY720-P, was prepared as described previously (Lu and Bittman
2006). Neurotrophin-3 (NT-3) and tumor necrosis factor-α (TNF-α) were from Peprotech
(Rocky Hill, NJ). All cell culture media components were from Sigma. The
phosphoinositide-3 kinase (PI3K) inhibitor LY294002, mitogen extracellular signal
regulated kinase kinase (MEK) inhibitor PD98059 and interferon-γ (IFN-γ) were from
Calbiochem (San Diego, CA). The SphK inhibitor N,N-dimethylsphingosine (DMS) was
obtained from Biomol (Plymouth Meeting, PA). Anti-phosphorylated ERK1/2 (P-ERK1/2)
and anti-total ERK1/2 (T-ERK1/2) antibodies were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA). Anti-phosphorylated Akt (P-Akt), anti-pan Akt (TAkt), anti-phosphorylated p38 mitogen-activated protein kinase (p38 MAP kinase) and
anti-phosphorylated c-Jun N-terminal kinase (JNK) antibodies were from Cell Signaling
Technology (Danvers, MA). The O4 antibody was kindly provided by Dr. Rashmi Bansal
(University of Connecticut).

Anti-β-actin antibody was from Sigma. All appropriate

secondary antibodies were obtained from Santa Cruz Biotechnology.

Isolation and culture of OLG progenitors: OLG progenitors were isolated from 2- to 3day-old Sprague–Dawley rat brains using a Percoll gradient followed by differential
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adhesion to eliminate the microglial cells, as described previously (Sato-Bigbee et al.
1999). The floating OLGs were plated in 48-well plates (Falcon) or 8-well chamber slides
(Nalge Nunc International, Naperville, IL) coated with 12.5 µL/well reduced growth
factor-Matrigel. The cells were maintained overnight in chemically defined medium
(CDM) [Dulbecco's modified Eagle's medium (DMEM) /F-12 Ham‟s medium (1: 1;
Invitrogen, Grand Island, NY) supplemented with 1 mg/mL fatty acid-free bovine serum
albumin, 50 µg/mL transferrin, 5 µg/mL insulin, 30 nM sodium selenite, 0.11 mg/mL
sodium pyruvate, 10 nM biotin, 20 nM progesterone, 100 µM putrescine, 15 nM
triiodothyronine]. Cultures prepared from these cells are comprised of immature OLG
progenitors that are either bipolar or possess several simple processes and are stained with
the A2B5/O4 antibodies (Sato-Bigbee et al. 1999). Astroglial contamination of these
cultures, as assessed by glial fibrillary acid protein staining, was less than 5%. Animal use
and isolation of OLGs were conducted in accordance with the guidelines from the National
Institutes of Health and approved by the Virginia Commonwealth University Animal Care
and Use Committee.

Microglial cultures and preparation of microglia-conditioned media: Microglial
cultures were prepared from 7-day old rat brains following the method described above for
isolation of OLG progenitors. After the Percoll gradient, the cell suspension containing
both OLGs and microglial cells was subjected to differential adhesion for 20 min. The
microglial cells that were firmly attached to the bottom of the plate were cultured in
DMEM medium containing 2% FBS. The microglia-conditioned medium was prepared as
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previously reported by Pang et al (Pang et al. 2000). For this, cultures grown to confluence
were washed 3 times with PBS and then incubated in CDM or CDM with 5 μg/mL LPS.
After 48 hrs, the medium was collected, filtered through a 0.45 micron syringe filter,
aliquoted and stored at -200C until use.

Treatment with FTY720 or FTY720-P: After 1 day in culture, OLG progenitors were
incubated for various times in DMEM/F12 with or without FTY720 or (S)-FTY720-P.
Cells were then processed for western blot analysis or for TUNEL assay as described
below. In experiments to evaluate the role of different protein kinases, the cells were preincubated for 10 min in the presence of the following specific kinase inhibitors: PD98059
(MEK inhibitor, 50 μM), LY294002 (PI3K inhibitor, 30 μM) or DMS (SphK inhibitor, 5
µM). Cultures were then incubated for 15 min in the presence of either 1 µM FTY720 or
the kinase inhibitor or a combination of both. For TUNEL assays, the inhibitors were
added 10 min before the addition of FTY720. In these experiments, PD98059 was used at a
concentration of 10 µM. Control media contained the same volume of vehicle in which the
inhibitors were dissolved (DMSO for LY294002 and PD98059; 4 mg/mL BSA for DMS).
Inhibitor concentrations are in agreement with those previously used by us and others to
specifically inhibit these kinases in OLGs (Cui et al. 2006; Sato-Bigbee et al. 1999).

Western blot analysis: OLG progenitor cultures containing equivalent numbers of cells
per well were lysed in 75 μL of 60 mM Tris-HCl buffer (pH 6.8) containing 10% glycerol,
2% sodium dodecyl sulfate (SDS), and 5% 2-mercaptoethanol. Fifteen µL samples were
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subjected to SDS-polyacrylamide gel electrophoresis in 12% acrylamide and the proteins
were electrotransferred to nitrocellulose. The membranes were then subjected to
immunoblot analysis as previously reported (Saini et al. 2005), with minor modifications.
Nonspecific antibody binding to the blots was blocked by incubation in 10 mM Na 2HPO4,
2.7 mM KCl and 137 mM NaCl, pH 7.4, (PBS) containing 3% nonfat dry milk and 0.05%
Tween-20 (blocking solution), for 1 h at room temperature. Blots were then incubated
overnight with anti-P-ERK1/2 (dil. 1:1,000), an antibody that reacts with p42 and p44
ERKs when phosphorylated at Tyr204 or anti-P-Akt (dil. 1:1,000), an antibody that
recognizes Akt when phosphorylated at Ser473 in the C-terminal regulatory domain. AntiT-ERK1/2 (dil. 1:1,000) and anti-T-Akt (dil. 1:1,000) antibodies were used to detect the
levels of total ERK1/2 and total Akt. β-actin levels detected with anti-β-actin antibody (dil.
1:2,000) were used as loading controls. After extensive rinsing with PBS, blots were
incubated for 30 min in blocking solution, followed by incubation with the appropriate
horseradish peroxidase (HRP)-conjugated secondary antibody for 3 h. All antibodies were
diluted in blocking buffer. After two 5-min rinses in PBS containing 0.05% Tween-20 and
four

10-min

rinses

in

PBS,

the

immunoreactive

bands

were

detected

by

chemiluminescence with Super Signal West Dura reagent (Pierce, Rockford, IL). The
relative amount of immunoreactive protein in each band was determined by scanning
densitometric analysis of the X-ray films using the NIH Image J program. After
quantification of the bands, values were divided by β-actin levels to correct for loading
differences.
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Detection of apoptotic cells: After fixation of the cells with 4% paraformaldehyde for 1 h
at room temperature, the number of apoptotic OLG progenitors was determined by
detecting DNA fragmentation using a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (In Situ Cell Detection Kit, Roche Diagnostics Corp.,
Indianapolis, IN), as previously reported (Saini et al. 2005). Fluorescein-labeled
nucleotides incorporated at 3'-hydroxyl ends were visualized by incubation with HRPconjugated anti-fluorescein antibody. The cells were then treated with diaminobenzidine
(DAB) (metal enhanced DAB substrate kit, Roche Diagnostics Corp.) to detect peroxidase
activity, followed by light microscopic examination. For each condition, at least 20 visual
fields containing approximately 200 cells each were analyzed.

[3H]Thymidine incorporation: After isolation, the OLG progenitors were plated on 48well plates previously coated with 12.5 µL/well reduced growth factor Matrigel and
maintained overnight in CDM. The next day, the medium was replaced with CDM
containing 1 μCi/mL [3H]thymidine (75Ci/mmol; Amersham, Piscataway,NJ), in the
presence or absence of 1 μM FTY720. After 18 h, the cultures were washed three times
with ice-cold PBS, followed by incubation with 20% trichloroacetic acid (TCA) for 1-2 hrs
at 40C. After four washes with 5% TCA, the cells were solubilized by incubation with 70%
formic acid at 37°C for 1 h. Aliquots were then used to determine the radioactivity by
liquid scintillation counting.
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Immunocytochemistry: OLG progenitors were plated in 8-well chamber slides (Nalge
Nunc International, Naperville, IL) coated with 12.5 µL/well reduced growth factor
Matrigel and maintained overnight in CDM. The next day, the medium was replaced with
CDM alone or supplemented with 1 μM FTY720, 50 ng/mL NT-3, or a combination of
both FTY720 and NT-3. The medium was replaced daily. On Day 5, the cells were fixed in
4% paraformaldehyde and immunocytochemistry was carried out as previously reported
(Sato-Bigbee et al. 1999). Non-specific antibody binding was blocked by incubation of the
cells for 1 hr in PBS containing 5% non-fat dry milk, 0.05% Tween-20, and 0.5% normal
goat serum (blocking solution). The cells were then incubated overnight with the O4
antibody (dil.1:3) in blocking solution. After several washes in PBS, the cells were
incubated for 30 min in blocking solution and for 2 h with Alexa 488-conjugated antimouse IgM (dil. 1:250). The cultures were analyzed using a Nikon Eclipse 800M
fluorescence microscope.

Statistical Analysis: Statistical analysis was performed by one-way analysis of variance
(ANOVA) and ad hoc Tukey–Kramer test (GraphPad Prism). Differences were considered
statistically significant when p-values were < 0.05.

RESULTS

Treatment of OLG progenitors with FTY720 results in increased phosphorylation of
ERK1/2 and Akt
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Since we previously found that S1P signaling plays a crucial role in the stimulation
of OLG progenitor survival by NT-3 (Saini et al. 2005) and given that most actions of
FTY720 are mediated by S1P receptors (Brinkmann and Lynch 2002), it was of interest to
examine the effects of FTY720 on OLG progenitors. Similar to S1P (Hida et al. 1999;
Saini et al. 2005), treatment with FTY720 activated ERK1/2 (Fig. 2.1A and B). A
significant effect was observed at a concentration of 1µM (Fig. 2.1A) and was maximal
within 15 min (Fig. 2.1B). FTY720 also induced phosphorylation of Akt in a similar doseand time-dependent manner (Fig. 2.1C and D). However, treatment with FTY720 did not
produce any significant changes in the levels of either total ERK or total Akt. Moreover,
FTY720 did not activate p38 MAP kinase or JNK, as determined with phospho-specific
antibodies (data not shown).
The stimulation of both ERK1/2 and Akt phosphorylation induced by FTY720 was
significantly reduced by the MEK inhibitor PD98059 (Fig. 2.2A and C) as well as by the
PI3K inhibitor LY294002 (Fig. 2.2B and D). Thus, FTY720 has a direct action on OLG
progenitors activating MEK/ERK1/2 and PI3K/Akt pathways, an effect that appears to
involve the interaction between both signaling cascades.

The FTY720-dependent induction of ERK1/2 and Akt phosphorylation requires
SphK activity and is mimicked by synthetic (S)-FTY720-P
Several studies have implicated FTY720-P, an S1P analog, as the bioactive form
responsible for FTY720 effects (Chiba et al. 2006). However, recent reports indicated that
FTY720 also has actions independent of its phosphorylation by SphKs and the need for
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Fig. 2.1. FTY720 induces ERK1/2 and Akt phosphorylation in OLG progenitors. A
and C: Cells were incubated in DMEM/F12 with or without 0.1 μM or 1 µM FTY720. B
and D: Cells were incubated for different times with 1 μM FTY720. P-ERK1/2 and P-Akt
levels were determined by western blot analysis. β-actin levels were used as loading
controls. Western blot figures correspond to representative experiments. Results are
expressed as percentage of controls (0 μM FTY720 for A and C; 0 time for B and D) and
represent the mean ± SEM from 5 independent experiments performed in triplicate.
*p<0.01, **p<0.002.
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Fig. 2.2. ERK1/2 and Akt phosphorylation induced by FTY720 involve MEK and
PI3K-dependent pathways. Cells were treated with or without 1 μM FTY720 in the
presence or absence of PD98059 (MEKi) (A and C) or LY294002 (PI3Ki) (B and D), as
described under “Methods”. P-ERK1/2 and P-Akt levels were determined by western blot
analysis. Results are expressed as percentage of controls (DMEM/F12 alone) and represent
the mean ± SEM from 3 independent experiments performed in triplicate. *p<0.05,
**p<0.005, ***p<0.0001.
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S1P receptors (Payne et al. 2006). These observations raised the question of whether
FTY720 action in the OLG progenitors requires the activity of a SphK isozyme. To
address this problem, we first investigated the capacity of FTY720 to stimulate ERK1/2
and Akt phosphorylation in cells treated with DMS, an inhibitor of both SphK1 and
SphK2. Figures 2.3A and B show that co-incubation with DMS abolished the FTY720dependent stimulation of both ERK1/2 and Akt phosphorylation, suggesting the
requirement of FTY720 phosphorylation by SphK.

To support this notion, we next

examined whether the effects of FTY720 in the OLG progenitors were mimicked by its
phosphorylated form, FTY720-P. These experiments were carried out using the active (S)enantiomer of FTY720-P which is the in vivo phosphorylated product of FTY720 (Albert
et al. 2005). Incubation of the OLG progenitors with (S)-FTY720-P resulted in a robust
increase in the phosphorylation of both ERK1/2 and Akt (Fig.2.4). This stimulation occurs
at a lower drug concentration than the one required for FTY720 (Fig. 2.4A and C).
Moreover, the kinetics of FTY720 versus (S)-FTY720-P actions indicate that (S)-FTY720P induces ERK1/2 and Akt activation faster than its non phosphorylated form, with
significant effects observed within 5 min (Figure 2.4B and D).

These findings suggest

that FTY720 action in the OLG progenitors is preceded by its phosphorylation by SphK. In
agreement, activation of ERK1/2 by (S)-FTY720-P was not affected by DMS (Fig 2.4E),
substantiating the notion that phosphorylation of FTY720 is required for its actions in the
OLG progenitors.
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Fig. 2.3. The FTY720-dependent induction of ERK1/2 and Akt phosphorylation is
inhibited by DMS. Cells were treated with or without 1μM FTY720 in the presence or
absence of 5 µM DMS. P-ERK1/2 (A) and P-Akt (B) levels were determined by western
blot analysis. Results are expressed as percentage of controls (DMEM/F12 alone) and
represent the mean ± SEM from 4 independent experiments performed in triplicate.
*p<0.05, **p<0.02, ***p<0.01.
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Fig. 2.4. ERK1/2 and Akt phosphorylation in OLG progenitors is also induced by
synthetic (S)-FTY720-P. A and C: Cells were incubated in DMEM/F12 with or without
0.1 μM or 1 µM (S)-FTY720-P as described in “Methods”. B and D: Cells were incubated
for different times with 0.1 μM (S)-FTY720-P.

P-ERK1/2 and P-Akt levels were

determined by western blot analysis. Results are expressed as percentage of controls (0 μM
(S)-FTY720-P for A and C; 0 time for B and D) and correspond to the mean ± SEM from 4
independent experiments performed in triplicate. *p<0.05, **p<0.005, ***p<0.001. E:
Cells were treated with or without 1μM (S)-FTY720-P in the presence or absence of 5 µM
DMS. P-ERK1/2 levels are expressed as percentage of controls (DMEM/F12 alone) and
represent the mean ± SEM from 2 independent experiments performed in triplicate.
*p<0.001.
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FTY720 blocks apoptosis of OLG progenitors caused by growth factor deprivation
ERK1/2 and Akt are both known to be involved in regulating OLG survival (Cui et
al. 2006; Ebner et al. 2000; Fragoso et al. 2004). Thus, the finding that FTY720 induces
ERK1/2 and Akt phosphorylation led us to investigate its possible effect on the survival of
OLG progenitors. To this end, the cell cultures were subjected to growth factor
deprivation, a condition that induces apoptosis of OLG progenitors (Saini et al. 2005) and
could be particularly important in the adult tissue where levels of growth factors are
significantly reduced when compared with the developing CNS. As detected by TUNEL
staining, overnight incubation in DMEM/F12 medium alone resulted in about 50% of the
cells undergoing apoptotic cell death (Fig. 2.5A). However, the number of apoptotic cells
was significantly reduced upon treatment with FTY720, indicating that this drug indeed
has a direct survival effect on the OLG progenitors. This effect truly reflects a change in
the percentage of surviving cells as [3H]thymidine incorporation experiments indicated that
FTY720 did not affect the proliferation of the OLG progenitors (Fig 2.5C).

The anti-apoptotic effect of FTY720 on OLG progenitors is blocked by inhibition of
PI3K and MEK signaling
Since FTY720 stimulated ERK1/2 and Akt phosphorylation, we then examined the
extent to which these two protein kinases were involved in mediating FTY720 effect on
OLG survival. For this, the capacity of FTY720 to block apoptosis was investigated in
cultures in which ERK1/2 and Akt signaling was blocked by inhibition of their upstream
activators MEK and PI3K. As observed before, FTY720 protected the cells from growth
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Fig. 2.5. FTY720 stimulates survival of the OLG progenitors. Cultures were
incubated for 22 h in DMEM/F12 with or without 1 μM FTY720. DNA fragmentation
was assessed by TUNEL assay. (A) The graph represents the number of TUNEL positive
cells as a percentage of total cells counted for each visual field. The micrographs show
representative fields. At least 20 visual fields were analyzed. *p<0.001. (B) Cultures were
incubated for 22 h in DMEM/F12 medium alone or supplemented with 1 μM FTY720 in
the presence or absence of the PI3K inhibitor LY294002 (30 µM) or the MEK inhibitor
PD98059 (10 µM). DNA fragmentation was assessed by TUNEL assay.

The graph

represents the number of TUNEL positive cells as a percentage of total cells counted for
each visual field. *p<0.001. (C) Cellular proliferation was assessed by [ 3H]Thymidine
incorporation as described in “Methods”. Cultures were incubated for 18 h in CDM in the
presence or absence of 1 μM FTY720. The results represent the means ± SEM from 2
independent experiments done in triplicate.
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factor deprivation. However, this effect was eliminated by co-treatment of the cultures with
PD98059 or LY294002 (Fig. 2.5B), suggesting that ERK1/2 and Akt signaling are required
for FTY720 to stimulate the survival of the OLG progenitors.

FTY720 and NT-3 cooperate to stimulate OLG survival and differentiation
NT-3 is known to stimulate the survival of OLGs and may play an important role
in myelin regeneration following CNS injury and demyelination (Barres et al. 1993; Jean
et al. 2003; McTigue et al. 1998; Saini et al. 2005).We have previously found that NT-3
stimulates the survival of OLG progenitors by a mechanism that involves the activation of
an S1P-dependent pathway (Saini et al. 2005). Thus, we next examined whether NT-3 and
FTY720 could cooperate to stimulate the survival of OLG progenitors. Cultures trea ted
with both FTY720 and NT-3 show significantly reduced number of apoptotic cells (15%)
which is lower than the percentage observed in cultures treated with either of these alone.
Interestingly, FTY720 appears to arrest the differentiation of OLG progenitors, an effect
that is overcome by co-treatment with NT-3. As shown in Fig 2.7, cultures treated with
FTY720 alone are predominantly composed of cells with a simple bipolar morphology
characteristic of immature OLGs. On the other hand, the majority of the cells that were
simultaneously exposed to both FTY720 and NT-3 exhibit complex and branched
processes, a morphology indicative of mature OLGs. Altogether, these observations
suggest that the combination of FTY720 and NT-3 could effectively promote the survival
as well as differentiation of OLGs.
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Fig. 2.6. FTY720 and NT-3 cooperate to promote OLG progenitor survival. Cultures
were incubated for 22 h in (A) DMEM/F12, (B) DMEM/F12 with 1 μM FTY720, (C)
DMEM/F12 with 50 ng/ml NT-3 or (D) DMEM/F12 with 1 μM FTY720 and 50 ng/ml
NT-3. Twenty-four hrs later, DNA fragmentation was assessed by TUNEL assay as
indicated in “Methods”. The graph represents the number of TUNEL positive cells as a
percentage of total cells counted for each visual field. *p<0.001.
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Fig. 2.7. NT-3 counteracts the inhibition of OLG progenitor maturation induced by
FTY720. Cultures were incubated for 5 days in (A) CDM (control), (B) CDM with 1 μM
FTY720, (C) CDM with 50 ng/ml NT-3 or (D) CDM with 1 μM FTY720 and 50 ng/ml
NT-3. After fixation, cells were immunostained with O4 antibody.
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FTY720 protects OLG progenitors from cell death induced by cytokines and
microglial activation
Death of OLGs in demyelinating diseases like MS is also thought to be
significantly increased by the presence of inflammatory cytokines such as TNF-α and IFNγ or by oxidative stress by free radical species that are produced by activated microglia
(McQualter and Bernard 2007). Indeed, TNF-α and IFN-γ markedly induced apoptosis of
the OLG progenitors (Fig 2.8A). Importantly, FTY720 effectively protected the cells from
this detrimental action of the two cytokines. Moreover, in agreement with previous reports
(Pang et al. 2000), treatment of OLG progenitors with conditioned media from LPSactivated microglial cells induced significant apoptotic cell death (Fig 2.8B). FTY720 also
protected the OLG progenitors from these deleterious actions of microglial activation (Fig
2.8B).
Altogether, these observations suggest that FTY720 can protect OLGs from many
of the factors implicated in their depletion in MS.

DISCUSSION

MS is a chronic degenerative disease in which demyelinating lesions of the CNS
are thought to be directly associated with an inflammatory process that involves the
activation and recruitment of macrophages, microglial cells and T lymphocytes
(Lucchinetti et al. 2005). For this reason, most current therapies include the use of antiinflammatory drugs. FTY720 is among the latest immunomodulators that exhibit
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Fig. 2.8. FTY720 protects OLG progenitors from apoptosis induced by cytokines and
microglial activation. (A) OLG progenitors were plated in 8-well chamber slides
previously coated with 12.5 μL/well reduced growth factor Matrigel and maintained in
CDM. The next day, the medium was replaced with CDM alone or supplemented with 1
μM FTY720, 100 ng/ml TNF-α, 100 ng/ml IFN-γ, 1 μM FTY720+100 ng/ml TNF-α, or 1
μM FTY720+100 ng/ml IFN-γ. After 22 h, apoptosis was determined by TUNEL assay.
The graph represents the number of TUNEL positive cells as a percentage of total cells
counted for each visual field. *p<0.01, **p<0.001. (B) OLG progenitors were isolated and
maintained overnight in CDM. The next day, the medium was replaced with either
microglia-conditioned medium (MCM) alone, LPS-treated microglia-conditioned medium
(MCM-LPS), MCM with 1 μM FTY720 (MCM+FTY720) or MCM-LPS with 1 μM
FTY720 (LPS-MCM +FTY720). After 48 hrs, the cells were analyzed by TUNEL assay.
*p<0.001.
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promising use for the treatment of MS (Kappos et al. 2006). Our findings suggest that
independently of its immunosuppressive and anti-inflammatory functions, FTY720 could
also have a beneficial effect in MS as a result of a direct action on OLGs. Importantly,
these effects occur at FTY720 concentrations which according to recent pharmacokinetic
studies on tissue distribution (Meno-Tetang et al. 2006a) are well within the FTY720
levels attained in brain following oral and intravenous administration.
We found that FTY720 protects cultured OLG progenitors from apoptotic cell
death, an action that is preceded by the activation of MEK/ERK1/2 and PI3K/Akt
signaling pathways.

The observation that FTY720 capacity to induce ERK1/2 and Akt

phosphorylation was abrogated by the SphK inhibitor DMS suggests that FTY720 actions
in the OLGs depend on its phosphorylation by a SphK isozyme most likely SphK2
(Zemann et al. 2006).
The ERK1/2 and PI3K/Akt signaling pathways have been implicated in promoting
OLG survival under different conditions (Cui et al. 2006; Ebner et al. 2000; Fragoso et al.
2004). We found that FTY720 stimulates these pathways in the OLG progenitors by a
mechanism that appears to require crosstalk between both signaling cascades. The results
indicated that the FTY720-dependent phosphorylation of Akt involved both its classical
activator PI3K, as well as a MEK-dependent pathway. At the same time, both PI3K- and
MEK-dependent pathways were required for ERK1/2 phosphorylation induced by
FTY720.

A close interdependence between PI3K/Akt and MEK/ERK1/2 signaling

pathways has also been reported in other cell types. A crucial role of ERK1/2 in Akt
activation was demonstrated in response to UVB irradiation, a situation that involved
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ERK1/2 dependent phosphorylation of the mitogen and stress-activated protein kinase 1
(Msk1) (Nomura et al. 2001). Another such example was observed in Akt activation
induced by oxidative stress, which was shown to require ERK1/2 dependent
phosphorylation of the adaptor protein p66shc (Hu et al. 2005).
It is important to note that the effect of FTY720-P on ERK activation in OLGs
appears to depend on the developmental stage of these cells, as a recent report failed to
detect ERK activation in morphologically mature OLGs (Osinde et al. 2007). In addition,
the signaling pathways triggered by FTY720 appear to also exhibit cell-specificity since
previous studies on T-lymphocytes have shown activation of p38 MAP kinase and JNK
without ERK stimulation (Matsuda et al. 1999). On the contrary, we did not detect
activation of p38 MAP kinase and JNK in the OLG progenitors (data not shown).
The present study further shows that FTY720 protects the OLG progenitors against
the deleterious actions of activated microglia as well as the inflammatory cytokines TNF-α
and IFN-γ, all of which have been implicated in the pathogenesis of MS (McQualter and
Bernard 2007). Previous studies (Fragoso et al. 2004) have shown that ERK has a
protective effect against apoptotic cell death of OLGs induced by reactive oxygen species,
known to be produced by activated microglia (Block et al. 2007). Akt has been shown to
play a crucial role in the IGF-1-mediated protection of OLG progenitors from apoptosis
induced by TNF-α (Pang et al. 2007). Thus, it is tempting to speculate that both ERK
and/or Akt pathways may be involved in the FTY720-mediated protection of OLG
progenitors against activated microglia and inflammatory cytokines.
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The possibility of a direct protective effect of FTY720 on OLGs is particularly
important as different studies have found that, together with myelin loss and axonal
degeneration (Trapp et al. 1999), OLG death is a feature of MS (Barnett and Prineas 2004;
Lucchinetti et al. 2004). Moreover, analysis of early MS lesions showed OLG death with
few or no infiltrating lymphocytes or macrophages, raising the possibility that at least in
some patients, OLG death may be a primary cause of MS (Barnett and Prineas 2004).
Thus, whether OLG death is a cause or a consequence of MS remains controversial
but it is now clear that the loss of these cells is a major component of the disease. The
finding that FTY720 is able to stimulate the survival of OLG progenitors is particularly
significant as these cells play a crucial role in the remyelination process by replacing lost
mature OLG pools (Keirstead and Blakemore 1999; Zhao et al. 2005).
It should also be considered that FTY720 could influence remyelination by effects
on other cells of the CNS. In this regard, it was recently demonstrated that (S)-FTY720-P
has a direct effect on cultured astrocytes, stimulating both their migration (Mullershausen
et al. 2007) and ERK phosphorylation (Osinde et al. 2007) via S1P receptors .
The present findings in OLG progenitors, together with the observation of
FTY720-P action in astrocytes, suggest that the mechanisms underlying the beneficial
effects of FTY720 in MS are more complex than previously speculated. On one side, the
therapeutic effect of FTY720 may result from its capacity to induce T lymphocyte
sequestration (Brinkmann and Lynch 2002; Chiba et al. 1998; Mandala et al. 2002),
interference with dendritic cell function (Lan et al. 2005), and inhibition of cytosolic
phospholipase A2 and eicosanoid production (Payne et al. 2006). On the other hand, in
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addition to these important immunomodulatory effects, a positive outcome in MS may also
reflect a direct action of FTY720 on different cell populations of the CNS, including cells
within the oligodendroglial and astrocytic lineages. Our results indicate that FTY720
exerts a direct anti-apoptotic protective effect on OLG progenitor pools, which may
potentially culminate in the replenishment of lost mature OLGs and thus, promote the
process of remyelination in MS. However, a key finding of this study is that the positive
effect of FTY720 on the survival of OLG progenitors contrasted with an apparent
inhibition of their maturation, an effect that was counteracted by NT-3. This observation
suggests that FTY720 treatment for MS should include the use of remyelinating agents
such as NT-3. This therapeutic approach would ensure both protection of existing OLG
progenitor pools against immune-mediated insults as well as stimulation of remyelination
by enhancing the differentiation of these cells.

CHAPTER 3
NT-3 ACTIVATES TRANSLATION INITIATION FACTORS IN
OLIGODENDROCYTES

In the previous section, we have demonstrated that NT-3, as a potent enhancer of
maturation, can override the inhibitory effects of FTY720 on the differentiation of OLG
progenitors. Hence, in this chapter, we have begun to address the potential mechanisms
underlying the differentiating effect of NT-3, with particular emphasis on the role of this
neurotrophin as a regulator of myelin protein synthesis.

ABSTRACT

Neurotrophin-3 (NT-3) regulates oligodendrocyte (OLG) differentiation by
mechanisms that remain poorly understood. Treatment of OLGs with NT-3 results in dosedependent stimulation of myelin basic protein (MBP) expression, attaining levels 10 -fold
higher than in controls. Interestingly, we found that this increase in protein levels occurs
in the absence of significant effects of NT-3 on MBP gene promoter activation or MBP
mRNA expression. These observations suggested that NT-3 up-regulates MBP protein
expression by a posttranscriptional mechanism. Such a possibility also raised the question
of whether NT-3 could have a more general effect, stimulating the expression of other
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OLG proteins. In agreement with this idea, NT-3 also induces the expression of two other
oligodendroglial

proteins,

myelin

associated

glycoprotein

(MAG)

and

myelin

oligodendrocyte glycoprotein (MOG). Consistent with this idea, we observed a 50%
increase in de novo protein synthesis following only a brief (15 min) exposure to NT-3, as
measured by

35

S-methionine incorporation. Such a remarkably fast response and increase

in protein synthesis is unlikely due to transcriptional activation and reinforced the
possibility that NT-3 may play a crucial role in regulating protein expression in OLGs by a
posttranscriptional mechanism.

In support of this possibility, we found that NT -3

stimulates the phosphorylation of two factors that regulate the initiation machinery,
eukaryotic initiation factor 4E (eIF4E) and its inhibitory binding partner 4E binding
protein 1 (4EBP1), both essential players in mediating cap-dependent protein synthesis.
This stimulation involves the NT-3 dependent activation of ERK1/2 and PI3K/mTOR
mediated signaling pathways. These observations suggest that NT-3 exerts a stimulatory
effect on myelination by a direct effect on the translational machinery.

INTRODUCTION

The myelin membrane serves as an insulating sheath that wraps around the axons
facilitating the saltatory conduction of nerve impulses. Thus, diseases affecting myelin
formation and maintenance have a profound effect on nerve function. Among these is
Multiple Sclerosis (MS), a demyelinating disease of the central nervous system (CNS) in
which myelin loss is believed to result from an autoimmune attack. In the CNS, the myelin
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membrane is made by the oligodendrocytes (OLGs), cells which also play a crucial role in
establishing axoglial interactions responsible for the clustering of sodium channels at the
nodes of Ranvier (Dupree et al. 1999; Rasband and Trimmer 2001). In addition to
demyelination, MS causes OLG damage and death, a major obstacle for achiving efficient
and complete remyelination (Miller and Mi 2007). Consequently, the ideal MS treatment
should address the need to replace both the lost myelin as well as functional mature
myelinating OLGs.
A single OLG contributes to the formation of several internodes on the same or
different axons. Thus, loss of even few of these cells can lead to extensive areas of
demyelination in multiple axons. Hence, understanding the molecular mechanisms that
govern OLG development is crucial to the design of therapies to stimulate myelin repair
and efficient remyelination of the damaged CNS. Before reaching their fully differentiated
phenotype, OLGs must undergo several well defined stages of development characterized
by the expression of specific antigenic markers. During embryogenesis, OLGs arise from a
pool of highly proliferative and migratory OLG progenitors within the ventricular and
subventricular zone (SVZ) (LeVine and Goldman 1988b). Interestingly, subsets of these
progenitors persist within the adult CNS and can be recruited to demyelinated areas in
experimental demyelination and in MS (Chang et al. 2000; Keirstead and Blakemore
1999). The survival, proliferation and maturation of OLG progenitors were shown to be
influenced by a variety of growth factors such as platelet derived growth factor (PDGF),
basic fibroblast growth (bFGF), insulin-like growth factor-1 (IGF-1) and neurotrophins
(Barres et al. 1993). Among the latter, neurotrophin-3 (NT-3), in particular, was shown to
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have several positive effects at multiple stages of OLG development. NT-3 is known to
induce survival and proliferation of OLG progenitors both in vitro and in vivo (Barres and
Raff 1994; Barres et al. 1994b). Developing OLGs express the NT-3 receptor TrkC and
knockout mice lacking the TrkC receptor or NT-3 have fewer numbers of OLG progenitors
as well as attenuated expression of OLG-specific markers (Cohen et al. 1996; Kahn et al.
1999; Kumar et al. 1998). Importantly, NT-3 has been shown to diminish the susceptibility
of cultured OLGs to glutamate induced excitotoxicity (Kavanaugh et al. 2000).
Furthermore, studies with animal models indicate that NT-3 may play an important role in
regulating OLG number and myelin regeneration following CNS injury and demyelination
(Jean et al. 2003; McTigue et al. 1998). In addition to its mitogenic and survival effects,
NT-3 was also shown to influence the in vitro differentiation of OLGs at early time points
(Heinrich et al. 1999). Furthermore, OLG precursor cells transfected with the NT-3 gene
showed a dramatic increase in myelin production in vitro (Rubio et al. 2004). However, the
molecular mechanisms responsible for NT-3 action on OLG maturation have yet to be
elucidated.
We now found that NT-3 causes a simultaneous stimulation in the expression of
several myelin proteins, including myelin basic protein (MBP), myelin associated
glycoprotein (MAG) and myelin oligodendrocyte glycoprotein (MOG). The present results
indicate that NT-3 activates in OLGs signaling pathways targeting the initiation factor 4E
(eIF4E) and its inhibitory protein 4E binding protein 1 (4EBP1), two crucial regulatory
components of the translational initiation machinery. These observations point towards a
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role of NT-3 in stimulating OLG protein synthesis by a post-transcriptional mechanism
that involves PI3K/mTOR and ERK dependent translational activation.

MATERIALS AND METHODS

Materials: Percoll was purchased from Sigma (St Louis, MO). Reduced growth factor
Matrigel was from Becton Dickinson (Franklin Lakes, NJ). Neurotrophin-3 (NT-3) was
from Peprotech (Rocky Hill, NJ). All cell culture media components were from Sigma Aldrich (St Louis, MO). The phosphoinositide-3 kinase (PI3K) inhibitor LY294002,
mitogen extracellular signal regulated kinase kinase (MEK) inhibitor PD98059 and
mammalian target of rapamycin (mTOR) inhibitor rapamycin were from Calbiochem (San
Diego, CA).

Anti-phosphorylated eukaryotic initiation factor 4E (P-eIF4E) and anti-

phosphorylated 4E binding protein1 (P- 4EBP1) antibodies were purchased from Cell
Signaling Technology (Danvers, MA). Anti-MBP and anti-MAG antibodies were from
Chemicon (Temecula, CA). Anti-MOG antibody (8-18C5) was a kind gift from Dr. Jeff
Dupree. Anti-β-actin antibody was from Sigma-Aldrich (St Louis, MO). All appropriate
secondary antibodies were obtained from Santa Cruz Biotechnology. Electrophoresis
reagents were from Bio-Rad Laboratories (Hercules, CA).

Isolation and culture of OLGs: OLGs were isolated from 7-day-old Sprague–Dawley
(Harlan Laboratories) rat brains using a Percoll gradient followed by differential adhesion
to eliminate remaining astrocytes and microglial cells, as described previously (Sato-
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Bigbee et al. 1999). The floating OLGs were plated in 48-well plates (Falcon) coated with
12.5 µL/well reduced growth factor-Matrigel. The cells were maintained overnight in
chemically defined medium (CDM) [Dulbecco's modified Eagle's medium (DMEM)/F-12
medium (1 : 1; Invitrogen, Grand Island, NY, USA) supplemented with 1 mg/mL fatty
acid-free bovine serum albumin, 50 µg/mL transferrin, 5 µg/mL insulin, 30 nm sodium
selenite, 0.11 mg/mL sodium pyruvate, 10 nm biotin, 20 nm progesterone, 15 nM
triiodothyronine, and 100 µm putrescine]. Cultures prepared from these cells are comprised
of immature OLGs most of which can be already labeled with the O4 antibody (SatoBigbee et al. 1999). Astroglial contamination of these cultures, as assessed by glial
fibrillary acid protein staining, was less than 5%. Animal use and isolation of OLGs were
conducted in accordance with the guidelines from the National Institutes of Health and
approved by the Virginia Commonwealth University Animal Care and Use Committee.

Treatment with NT-3: In experiments investigating the expression of myelin proteins,
one day after isolation, cells were incubated for various times in CDM with or without
different concentrations of NT-3. In short term experiments investigating signaling events,
the cells were incubated in DMEM/F12 with or without NT-3. Cells were then processed
for western blot analysis, promoter assays or real-time RT-PCR as described below. In
experiments evaluating the role of different protein kinases, the cells were pre-incubated
for 10 min in the presence of the following specific kinase inhibitors: PD98059 (MEK
inhibitor, 10 μM), LY294002 (PI3K inhibitor, 30 μM) or Rapamycin (25 nM). Cultures
were then incubated for 15 min in the presence of either 50 ng/ml NT-3 or the kinase
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inhibitor or a combination of both. Control media contained the same volume of vehicle in
which the inhibitors were dissolved (DMSO). Inhibitor concentrations are in agreement
with those previously used by us and others to specifically inhibit these kinases in OLGs
(Baron et al. 2000; Cui et al. 2006; Flores et al. 2000; Sato-Bigbee et al. 1999).

MBP promoter assay: The -1323-luc construct containing MBP gene sequences from 1,323 to +30 upstream of the luciferase coding region in pGL3Basic was a generous gift of
Dr. Robin Miskimins (Sanford School of Medicine of the University of South Dakota,
Vermillion, SD) (Miskimins et al. 2002). For transfection, cultures plated in 24 well plates
and containing equal cell numbers (60% confluent) were incubated with 1 µg/well of the
luciferase MBP construct in the presence of 1.5 µL GeneJammer reagent (Stratagene, La
Jolla, CA, USA), following the manufacturer's recommendations. After 3 h, the
transfection medium was replaced by CDM. Following overnight incubation, the
transfected cells were incubated for various time points in CDM in the presence or absence
of 50 ng/mL NT-3. At the end of the treatment, cell extracts were prepared and assayed for
luciferase activity using the Luciferase Assay System (Promega, Madison, WI, USA). βactin levels were determined by western blot analysis of the cell extracts to ensure equal
cell numbers for each condition.

Real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR): Total RNA
was isolated from OLG cultures using the RNeasy Micro Kit (Qiagen, Valencia, CA). For
real-time qRT-PCR, oligo(dT)-primed cDNAs were synthesized using the Sensiscript RT
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kit (Qiagen, Valencia, CA). PCR was performed on a Chromo 4 Four-Color Real-Time
System (BioRad, Hercules, CA) using the iQ SYBR Green Supermix. The following
primer pairs were used at the indicated annealing temperatures: MBP (exon 2 containing
isoforms) forward (5′-ACTTGGCCACAGCAAGTACCATGGACC-3′), reverse (5′-TTG
TAC ATG TGG CAC AGC CCG GAC-3′) and MBP (all isoforms) forward (5‟-GTG
ACA CCT CGT ACA CCC CCT CCA T-3‟), reverse (5‟-GCT AAA TCT GCT GAG
GGA CAG GCC T-3‟). For normalization, amplification of 18S rRNA was performed:
forward (5′-TTC GGA ACT GAG GCC ATG AT-3′), reverse (5′-TTT CGC TCT GGT
CCG TCT TG-3′), 60°C. PCR conditions were as follows: 95°C for 15 min followed by
34 cycles at 94°C for 15 s, annealing temperature for 20 s, and 72°C for 20 s. For relative
comparison of MBP mRNA levels in the presence or absence of NT-3, the ΔΔCT method
was used (Livak and Schmittgen 2001)

Western blot analysis: OLG cultures containing equivalent numbers of cells per well
were lysed in 60 mM Tris-HCl buffer (pH 6.8) containing 10% glycerol, 2% sodium
dodecyl sulfate (SDS), and 5% 2-mercaptoethanol. Samples for analysis of MAG were
prepared in the above buffer under non-reducing conditions in the absence of 2mercaptoethanol. Fifteen µL samples were subjected to SDS-polyacrylamide gel
electrophoresis in 12% acrylamide and the proteins were electrotransferred to
nitrocellulose. The membranes were then subjected to immunoblot analysis as previously
reported (Saini et al. 2005), with minor modifications. Nonspecific antibody binding to the
blots was blocked by incubation in 10 mM Na 2HPO4 , 2.7 mM KCl and 137 mM NaCl, pH
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7.4, phosphate buffered saline (PBS) containing 3% nonfat dry milk and 0.05% Tween-20
(blocking solution), for 1 h at room temperature. Blots were then incubated overnight with
the following primary antibodies: anti-MBP (dil. 1:100), anti-MAG (dil. 1:1,000), antiMOG (dil. 1:25), anti-phospho-eIF4E (dil. 1:1,000) and anti-phospho-4EBP1 (dil.
1:1,000). After extensive rinsing with PBS, blots were incubated for 30 min in blocking
solution, followed by incubation with the appropriate horseradish peroxidase (HRP)conjugated secondary antibody for 3 h. All antibodies were diluted in blocking buffer.
After two 5-min rinses in PBS containing 0.05% Tween-20 and four 10-min rinses in PBS,
the immunoreactive bands were detected by chemiluminescence with Super Signal West
Dura reagent (Pierce, Rockford, IL). β-actin levels detected with anti-β-actin antibody (dil.
1:2,000) were used as loading controls.The relative amount of immunoreactive protein in
each band was determined by scanning densitometric analysis of the X-ray films using the
NIH Image J program.

In vitro measurement of protein synthesis using [ 35S]Methionine: After isolation, OLGs
were plated in 24-well plates (Falcon) coated with 25 µL/well reduced growth factorMatrigel. The cells were maintained overnight in CDM. The next day, the medium was
changed to DMEM/F12. After 3 hours, the cells were incubated for 15 min in DMEM/F12
containing 10µCi 35S- Methionine (1,000 Ci/mmol sp. activity) with or with 50 ng/ml NT 3. At the end of the incubation, cultures were rinsed three times with ice cold PBS and the
cells were then lysed by incubation for 30 min in 250 µl of 0.5M NaOH at 37 0 C. The
lysates were collected in microcentrifuge tubes and proteins were precipitated by addition
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of 250 µl 20% trichloroacetic acid (TCA) followed by incubation on ice for 1-2 hours.
After centrifugation, the resultant pellet was washed twice with 5% TCA and finally
solubilized by addition of 100 µl formic acid (70%) and incubation at 37 0C for 1 hour.
Aliquots were used to determine the radioactivity by liquid scintillation counting.

Statistical Analysis: Statistical analysis was performed by one-way analysis of variance
(ANOVA), ad hoc Tukey–Kramer test and Student‟s t-test (GraphPad Prism). Differences
were considered statistically significant when p-values were < 0.05.

RESULTS

Treatment of OLGs with NT-3 upregulates MBP expression without altering MBP
gene promoter activation or MBP mRNA levels
In agreement with previous reports (Du et al. 2003; Rubio et al. 2004), our results
showed that NT-3 is a potent inducer of MBP expression. In these experiments, developing
OLGs were cultured for 3 days in the presence or absence of different concentrations of
NT-3. As shown in Figure 3.1, treatment of the cell cultures with NT-3 causes a dosedependent increase in MBP expression, attaining levels that were about 10-fold higher than
in controls.
To understand the mechanisms underlying this stimulatory action of NT-3, we next
investigated whether this neurotrophin could have an effect on MBP gene activity. For
this, the cells were transfected with a reporter construct containing the luciferase gene
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Figure 3.1: Treatment of OLGs with NT-3 results in increased MBP expression.
OLGs were isolated from 7 day old rat brains and cultures were incubated for 3 days in
CDM with or without 5, 10, 25, 50 ng/ml NT-3. MBP levels were determined by western
blot analysis. -actin levels were used as loading controls. Western blot figures correspond
to representative experiments. Results in the bar graph are expressed as percentage of
controls (0 ng/ml NT-3) and represent the mean ± SEM from 3 independent experiments
performed in triplicate. * p< 0.005
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under the control of the MBP gene promoter, and cultures were then incubated for
different times in media with and without NT-3. Since the cells were exposed to a
chemically defined medium that induces OLG differentiation (Sato-Bigbee et al. 1999), an
expected increase in MBP gene promoter activity was observed, even in control cells in the
absence of NT-3, with extended time in culture (Figure 3.2). Surprisingly, inspite of the
dramatic elevation in MBP protein levels observed in cultures treated with NT-3, this
neurotrophin did not cause any significant increase in MBP gene promoter activity at any
time point studied.
Furthermore, comparison with control cultures indicated that OLGs treated with
NT-3 did not exhibit any major differences in MBP mRNA levels (Figure 3.3). The
different MBP isoforms are generated by alternative splicing of a single gene (de Ferra et
al. 1985) and both MBP gene activity and splicing are developmentally regulated
(Campagnoni 1988). Because MBPs species expressed during early OLG maturation are
predominantly represented by the exon-2 containing isoforms, real-time RT-PCR analysis
in these studies used two different sets of primers to distinguish between all MBPs and
exon-2 containing MBP mRNA transcripts. Analysis of exon-2 containing transcripts,
corresponding to the 17 and 21.5 kDa MBP isoforms, indicated a 50% increase after a 12
hour incubation period with NT-3 (Figure 3.3B). However, except for this transient
stimulation, no other major differences in MBP mRNA levels between controls and treated
cells could be detected at any other time of NT-3 exposure and regardless of isoformspecific exon expression.
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Figure 3.2: NT-3 does not induce any major changes in MBP gene promoter activity.
OLGs were transfected with a reporter construct containing the luciferase gene under the
control of the MBP gene promoter using Gene Jammer transfection reagent. Cultures were
then incubated for 12, 24 and 48 hours in CDM in the absence (control) or presence of NT3 (50 ng/ml). The luciferase activity in the samples is expressed as optical units. The
results are the mean ± SEM from three independent experiments performed in triplicate.
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Figure 3.3: Treatment of OLG cultures with NT-3 does not have a significant effect
on MBP mRNA levels. OLGs cultures were incubated for 12, 24 and 48 hours in CDM
with or without NT-3. Levels of mRNA for MBP were determined by real-time qRT-PCR
using appropriate primers. 18S ribosomal RNA was used for normalization. The bar graphs
represent the steady-state levels of MBP mRNA relative to the controls (not treated with
NT-3) which have been set to 1. (A) Levels of MBP mRNA containing all exons
(B) Levels of MBP mRNA containing only exon 2. The results are the means ± SD from
two independent experiments done in duplicates. *p < 0.05
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The stimulatory effect of NT-3 is not restricted to MBP expression
The lack of promoter activation or significant changes in mRNA levels described
above suggested that NT-3 up-regulates MBP expression by a posttranscriptional
mechanism. Such possibility also raised the question of whether this neurotrophin could
have a more general effect, also stimulating the expression of other oligodendroglial
proteins. To test this possibility, we next investigated the potential action of NT-3 on the
expression of two additional myelin/oligodendroglial proteins, MAG and MOG.
As shown in Figure 3.4, similar to the results observed for MBP, exposure of the
OLG cultures to NT-3 results in a significant increase in the levels of both MAG and
MOG.
Furthermore, a

35

S-methionine incorporation assay demonstrated that, even within

only 15 minutes of exposure to NT-3, there is already a 50% increase in 35 S labeling of the
TCA precipitable protein, a parameter indicative of de novo protein synthesis in the cells
(Figure 3.5). Such a remarkably fast response and measurable increase in protein synthesis
in response to NT-3 is unlikely due to transcriptional activation.

Together with the

previous observations, this later result rather reinforced the possibility that NT-3 may play
a crucial role in regulating protein expression in the OLGs by a posttranscriptional
mechanism.
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Figure 3.4: Treatment of OLGs with NT-3 results in increased expression of MAG
and MOG. OLG cultures were incubated for 3 days in CDM with or without 5, 10, 25, 50
ng/ml NT-3. MAG and MOG levels were determined by western blot analysis. -actin
levels were used as loading controls. Western blot figures correspond to representative
experiments. Results are expressed as percentage of controls (0 ng/ml NT-3) and represent
the mean ± SEM from two independent experiments performed in triplicate. * p< 0.05,
**p<0.005
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Figure 3.5: NT-3 increases de novo protein synthesis in OLGs. OLG were incubated for
15 minutes in DMEM/F12 containing 10 µCi/well

35

S- methionine, in the presence or

absence of 50 ng/ml NT-3. Incorporation of 35 S methionine into total protein was estimated
by scintillation counting as described under “Materials and Methods”. The results are the
mean ± SEM from 3 independent experiments done in triplicate. *p<0.005
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NT-3 induces the phosphorylation of factors that control the initiation of protein
translation
The results described above lead us to investigate whether NT-3 could stimulate
some of the steps involved in mRNA translation, in particular the initiation phase, a key
regulatory step in eukaryotic protein synthesis (Sonenberg and Gingras 1998). Among the
factors that regulate initiation, eukaryotic initiation factor 4E (eIF4E) and its inhibitory
binding partner 4E binding protein 1 (4EBP1) are the most essential players in mediating
cap-dependent protein synthesis (Svitkin et al. 2005). Phosphorylation of 4EBP1 releases
eIF4E into the cytoplasm, step which is followed by eIF4E phosphorylation and binding to
the mRNA cap. This cascade of events triggers the initiation machinery into action and
translation begins (Raught and Gingras 1999).
In support of a role for NT-3 in stimulating protein synthesis initiation, we found
that OLGs incubated with NT-3 exhibited a sustained increased in eIF4E phosphorylation
(Figure 3.6A).

Therefore, we next examined if NT-3 could also cause 4EBP1

phosphorylation. As shown in Figure 3.6B, this is indeed the case as treatment of the cells
with NT-3 was accompanied by a robust increase in phosphorylation of 4EBP1.

NT-3 stimulates eIF4E and 4EBP1 phosphorylation by ERK and PI3K/mTOR
mediated pathways
In agreement with previous results from this and other laboratories (Cohen et al.
1996; Johnson et al. 2000; Kumar et al. 1998; Ness et al. 2002), treatment of OLGs with
NT-3 induces rapid activation of ERK1/2 and Akt (Figures 3.7A and 3.8A). Importantly,

112

Figure 3.6: Treatment of OLGs with NT-3 induces phosphorylation of the initiation
factors eIF4E and 4EBP1. A and B: Cells were incubated in DMEM/F12 with or without
50 ng/ml NT-3. P-eIF4E and P-4EBP1 levels were determined by western blot analysis. βactin levels were used as loading controls. Western blot figures correspond to
representative experiments. Results are expressed as percentage of controls (0 time) and
represent the mean ± SEM from 3 independent experiments performed in triplicate.
*p<0.05, **p<0.005
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Figure 3.7: The stimulation of eIF4E and 4EBP1 phosphorylation by NT-3 involves
an ERK-dependent pathway. Cells were treated with or without 50 ng/ml NT-3 in the
presence or absence of 10 µM PD98059 (MEKi) as described under “Materials and
Methods”. P-ERK (A), P-eIF4E (B) and P-4EBP1(C) levels were determined by western
blot analysis. Results are expressed as percentage of controls (0 time for A, DMEM/F12
alone for B and C) and represent the mean ± SEM from 3 independent experiments
performed in triplicate. *p<0.05, **p<0.005, ***p<0.0001
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Figure 3.8: The NT-3-dependent induction of eIF4E and 4EBP1 phosphorylation is
inhibited by LY294002 and rapamycin. Cells were treated with or without 50 ng/ml NT3 in the presence or absence of 30 µM LY294002 (PI3K inhibitor) (B and C) or 25 nM
rapamycin (mTOR inhibitor) (D and E). P-Akt (A) and P-eIF4E (B and D) and P-4EBP1
(C and D) levels were determined by western blot analysis. Results are expressed as
percentage of controls (0 time for A, DMEM/F12 alone for B, C, D and E) and represent
the mean ± SEM from 3 independent experiments performed in triplicate. *p<0.05,
**p<0.005.

117

118
these two kinase systems were implicated in regulating the initiation of protein synthesis in
a variety of cells and thus, we next examined their involvement as mediators in the
induction of eIF4E and 4EBP1 phosphorylation by NT-3. Studies have pointed towards a
putative role of the MAPK/ERK pathway in eIF4E phosphorylation as demonstrated by an
increase in phosphorylated eIF4E in cells transformed by ras- or src- oncogenes
(Frederickson et al. 1991; Rinker-Schaeffer et al. 1992). In agreement with this function,
the capacity of NT-3 to induce eIF4E phosphorylation in the OLGs was significantly
reduced by PD98059, a kinase inhibitor that blocks phosphorylation of MEK, the kinase
that activates ERK1/2 (Fig 3.7B). Unexpectedly, inhibition of MEK also blocked NT-3
ability to stimulate 4EBP1 phosphorylation (Fig 3.7C) suggesting that in OLGs, signaling
through ERK also plays a key role in regulating 4EBP1.
Several lines of evidence also showed that the intracellular signaling cascade
leading to 4EBP1 phosphorylation involves several components of the PI3K pathway and
its downstream effector Akt/PKB (Gingras et al. 1998). In addition, 4EBP1
phosphorylation was also shown to be dependent upon the FKBP12- rapamycin associated
protein/mammalian target of rapamycin (FRAP/mTOR) kinase (Brunn et al. 1997a; Brunn
et al. 1997b; Burnett et al. 1998; Hara et al. 1997). Therefore, we used LY294002, a
specific inhibitor of the PI3K/Akt pathway as well as the mTOR inhibitor rapamycin to
investigate the role of these kinase systems in the induction of phosphorylation of 4EBP1
by NT-3. The results indicated that both LY294002 (Figure 3.8C) and rapamaycin (Figure
3.8E) prevented the stimulation of 4EBP1 phosphorylation by NT-3.

Interestingly,

rapamycin also dramatically decreased the control values to negligible levels of detection,
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suggesting that an mTOR mediated pathway plays a crucial role in maintaining basal levels
of protein synthesis in the OLGs.
To our knowledge, the involvement of the Akt and mTOR pathways in controlling
eIF4E activation remains unknown. Interestingly, we did observe a significant reduction in
the NT-3-mediated activation of eIF4E in the presence of LY294002 (Fig 3.8B) and
rapamycin (Fig 3.8D), indicating that Akt and mTOR pathways do play a role in regulating
eIF4E activation in response to NT-3 stimulation.
Altogether, these results indicate the involvement of both ERK and PI3K/mTOR
mediated pathways in regulating the translation initiation machinery in OLGs. These
pathways participate in the mechanisms leading to phosphorylation of eIF4E and 4EBP1 in
response to NT-3 stimulation (Figure 3.9). Furthermore, these observations suggest that
NT-3 could play a crucial role in upregulating protein expression in myelinating OLGs by
modulating the activity of factors critical to the control of protein synthesis initiation.

DISCUSSION

NT-3 has been shown to play multiple roles in OLG development ranging from
stimulation of survival and proliferation (Barres et al. 1994b; Barres et al. 1993; Bertollini
et al. 1997; Johnson et al. 2000; Kumar et al. 1998; Robinson and Miller 1996; Wilson et
al. 2003) to the enhancement of cell differentiation (Coelho et al. 2007; Du et al. 2003;
Heinrich et al. 1999; Yan and Wood 2000).

However, while several studies have

investigated the signaling pathways leading to the effects of NT -3 on survival and
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Figure 3.9: Proposed mechanism of NT-3 action as a stimulator of translation
initiation in OLGs. Binding of NT-3 to the TrkC receptor activates a classical MAPK
pathway involving Ras-GTP/Raf, MEK1/2, ERK 1/2 and MNK 1/2 as well as the
PI3K/Akt/mTOR cascade leading to the phosphorylation of eIF4E and 4EBP1.
Phosphorylated eIF4E is released by 4EBP1 and can bind to eIF4A and eIF4G to form the
eIF4F initiation complex, allowing the initiation of protein translation to begin.

121

122
proliferation (Cohen et al. 1996; Heinrich et al. 1999; Johnson et al. 2000; Ness et al. 2002;
Saini et al. 2005; Saini et al. 2004), little is known about the mechanisms underlying the
actions of this neurotrophin on OLG maturation.
In our attempt to investigate the signals involved in increasing protein expression
during OLG differentiation in response to NT-3, we have now uncovered a novel effect of
this neurotrophin as a regulator of the eukaryotic initiation factors eIF4E and 4EBP1.
These two proteins are key players in the initiation phase, the first and rate controlling step
of protein translation (Hershey 1991). The initiation phase is a multi-step process that
begins with the recruitment of the heterotrimeric complex eIF4F to the mRNA 5‟-end cap,
finally causing unwinding of the mRNA and recruitment of the 40S ribosomal subunit.
Binding of the eIF4F complex to the mRNA is mediated by its cap-binding subunit eIF4E
(Gingras et al. 1999), a factor that is normally maintained at limiting levels by controlled
gene transcription (Lynch et al. 2005; Schmidt 2004) and proteosome-dependent
degradation (Murata and Shimotohno 2006).
The present observation of a stimulatory effect of NT-3 on eIF4E phosphorylation
at Ser 209 is particularly important because phosphorylation at this site was shown to
increase both eIF4E affinity for capped mRNA and its binding with eIF4G, an associated
scaffolding protein required in the assembly of the initiation machinery (Bu et al. 1993;
Minich et al. 1994). Furthermore, our findings showed that NT-3 could also stimulate
eIF4E activity and concomitant translational initiation through the observed increase in
4EBP1 phosphorylation. 4EBP1 plays a crucial role as a negative regulator of translation
because it dimerizes with eIF4E, competitively blocking the binding of this initiation factor
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with eIF4G (reviewed by Gingras et al. 1999). However, this inhibitory effect on the
assembly of the translational machinery is known to be reversed by 4EBP1
phosphorylation, a process that results in disruption of eIF4E-4EBP1 complex formation.
In agreement with different studies investigating other cell systems and stimuli
(Brunn et al. 1997a; Brunn et al. 1997b; Burnett et al. 1998; Hara et al. 1997), we found
that NT-3 upregulates 4EBP1 phosphorylation in the OLGs by a PI3K/mTOR dependent
pathway. Interestingly, our results showed that the NT-3 dependent phosphorylation of
4EBP1 is also dependent on MEK suggesting that at least in OLGs, an ERK1/2 mediated
pathway also controls 4EBP1 activity. Likewise, the present results showed that both MEK
and PI3K/mTOR dependent pathways are also involved in the NT-3 dependent
phosphorylation of eIF4E. Studies have shown that the MAPK pathway acting through
ERK converge with the p38 MAPKs at MAP kinase interacting kinases 1 and 2 to
phosphorylate eIF4E (reviewed by Gingras et al. 1999). It is possible to hypothesize that
the observed participation of a PI3K/mTOR pathway on eIF4E phosphorylation reflects the
sequestration of this factor by 4EBP1 since decreased 4EBP1 phosphorylation as a
consequence of PI3K/mTOR pathway inhibition would result in increased 4EBP1-eIF4E
complex formation.
The present results in OLGs add to a growing list of different studies supporting the
role of translation initiation as a crucial regulatory mechanism in CNS development and
function. Another neurotrophin, BDNF, has been shown to induce local protein synthesis
in primary cultured cortical neurons by inducing phosphorylation of the initiation factor
eIF4E and its binding protein 4EBP1 (Takei et al. 2001). Moreover, several lines of
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evidence implicate translational control by both ERK and mTOR signaling in the induction
of long-lasting synaptic plasticity and memory (Banko et al. 2006; Gelinas et al. 2007;
Kelleher et al. 2004; Tang et al. 2002). It is important to point out that although several
lines of evidence indicate that translational control mechanisms play a crucial role in cell
development (de Moor and Richter 2001), little is known about the importance of these
regulatory processes in OLG biology and myelination.

Interestingly, recent studies from

Lin et al. (Lin et al. 2008) showed that another component of the initiation machinery,
eIF2, a complex that interacts with the methionyl initiator tRNA, was shown to be
involved in the regulation of the integrated stress response in OLGs, a process that is
responsible for the protective effects of interferon-γ (IFN-γ) in EAE (Lin et al. 2007).
These authors demonstrated that by activation of the pancreatic endoplasmic reticulum
kinase (PERK) and subsequent phosphorylation of the α subunit of the eIF2 complex, IFNγ could promote OLG survival in immune-mediated demyelination. Moreover, the
importance of translational initiation in OLGs is underscored by the observation that
alterations in eIF2α kinases in these cells have been linked to schizophrenia (Carter 2007),
and defects of initiation eIF2B complex in OLGs may be responsible for childhood ataxia
with CNS hypomyelination or vanishing white matter leukoencephalopathy, a fatal brain
disorder (Richardson et al. 2004).
Our present results show for the first time that ERK and PI3K/mTOR mediated
pathways target the translation initiation machinery in developing OLGs and support the
idea that activation of translational initiation by NT-3 could play a crucial role during OLG
maturation and myelination. These findings encourage further research into translational
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control in OLGs and offer the possibility of new targets to stimulate efficient myelin
protein synthesis, and therefore remyelination, in demyelinating diseases such as MS.

CHAPTER 4
GENERAL DISCUSSION AND FUTURE DIRECTIONS

MS is the leading cause of neurological disability in young adults. It is estimated
that more than 400,000 people in the United States alone are affected by the disease while
more than 2.5 million people may be affected worldwide. While a definitive cure has yet to
be discovered, major strides in understanding MS have been made over the past decade.
Work by various groups has lead to the knowledge of the cell types involved and the
immunological aspects of this crippling CNS disorder. Consequently, these studies have
opened up the field of MS treatment to an array of therapeutic options ranging from drugs
targeting the immune cells to those which may promote remyelination and axonal repair.
Although the process of remyelination can occur with remarkable efficiency in
experimental models of demyelination, remyelination in MS patients is often incomplete
and accompanied by axonal damage. Therefore, it is crucial to identify potential targets
involved in this phenomenon.
Transplantation of myelinogenic cells is a potential means of inducing
remyelination, an approach that has been studied for over two decades. This particular
mode of therapy has been derived from experiments with a number of demyelinating
models in which myelinating cells from various sources have been locally injected into
focal areas of experimentally-induced demyelination. However, the feasibility of this idea
has declined after a thorough evaluation of the effects of injecting adult neural precursors
into EAE mouse models intravenously or intracerebroventricularly (Pluchino and Martino
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2005). Although, these studies show that such progenitor cell therapy effectively attenuates
the pathology observed in these mice (Ben-Hur et al. 2003; Pluchino et al. 2003), this
effect does not seem to be the result of regeneration, but rather due to an
immunomodulatory effect. The injection of these cells induced a reduction in both the
infiltration of immune cells into lesions as well as the release of inflammatory cytokines
(Einstein et al. 2007; Einstein et al. 2006). Subsequently, this stem cell approach to
remyelination has shifted from local injection towards systemic delivery of cells, allowing
further enhancement of their immunomodulatory properties rather than their potential
regenerative capacity.
An alternative approach to remyelination would be to activate the endogenous
regenerative process so that it works more efficiently in demyelinating disease. Hence, our
work focuses on understanding the developmental biology of OLG progenitors as they
form the major pool of endogenous remyelinating cells in the adult CNS.
FTY720 is among the latest immunomodulators that exhibit promising use for the
treatment of MS (Kappos et al. 2006). The studies presented in the first part of this thesis
suggest that in addition to its immunosuppressive and anti-inflammatory functions,
FTY720 could also have a beneficial effect in MS as a result of a direct action on OLGs
(Coelho et al. 2007). Although our studies have tested the effects of FTY720 in cultured
cells, it is important to note that, according to recent pharmacokinetic studies on tissue
distribution (Meno-Tetang et al. 2006a), the FTY720 concentrations we have used are
well within the drug levels attained in brain following oral and intravenous administration.
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Our earlier findings suggested the involvement of the bioactive lipid S1P in
mediating the survival-inducing effects of NT-3 in OLG progenitors (Saini et al. 2005).
We found that FTY720, like its analog S1P, stimulated the survival of these cells. FTY720
protected the OLGs against growth factor deprivation-induced cell death, an important
environmental constraint in the adult CNS. In this regard, it is important to consider the
physiological factors that affect the ability of myelinating cells to remyelinate the CNS,
notably age. This may be very relevant for a disease such as MS which has a course that
runs over several decades. Experimental evidence in rats shows that the efficiency of
remyelination declines rapidly with age (Li et al. 2006; Sim et al. 2000). Several theories
can be proposed for why remyelination is less efficient in older animals. One possibility is
that the number of progenitor cells available in white and grey matter decreases with age.
Yet, there is no evidence from experimental models to indicate that there is a reduction in
the number of these cells in older animals, which are present throughout white and grey
matter (Sim et al. 2002). However, in pathological conditions of the adult CNS, like in
MS, there is destruction and subsequent decrease in the number of OLG progenitors (Foote
and Blakemore 2005). Thus, administration of trophic factors or drugs that provide these
cells with a survival advantage may compensate for the insufficient availability of growth
factors in the adult CNS and therefore, may have a positive effect on remyelination. Our
findings suggest that FTY720 shows promise to act at such a level. Furthermore, our
present study shows that FTY720 protects the OLG progenitors against the deleterious
actions of activated microglia as well as the inflammatory cytokines TNF-α and IFN-γ, all
of which have been implicated in the pathogenesis of MS (McQualter and Bernard 2007).
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The following reports concurred with our observations and described a positive effect of
FTY720 on cultured OLGs both from adult and neonatal rats, protecting them against
apoptosis induced by serum withdrawal (Jung et al. 2007). Importantly, latter studies using
OLGs derived from human fetal CNS (progenitors) and human adult CNS (mature OLGs)
determined that FTY720 modulated process extension and survival. These effects were
based on both the length of treatment and the dose of the drug: while a 1 day short-term
treatment caused initial process retraction, a 2 day incubation resulted in process extension
and enhanced cell survival (Miron et al. 2008a; Miron et al. 2008b).
Although FTY720 demonstrated positive effects on survival, similar to the results
observed for S1P, this drug was found to be an inhibitor of OLG progenitor migration
through activation of the S1P5 receptor (Novgorodov et al. 2007). S1P5 is predominantly
expressed in OLGs throughout their life span (Jaillard et al. 2005; Terai et al. 2003),
including in OLG progenitors, which migrate from the site of their emergence toward their
final destination, mainly the future white matter tracts in the developing CNS. Along with
S1P5, these cells also express S1P1, S1P2, and S1P3 receptors. Remarkably, S1P
selectively engages the S1P5 receptor signaling pathway to inhibit OLG progenitor
migration despite the presence of S1P2, another S1P receptor capable of influencing cell
migration. These results highlight the strong specificity of the effect of S1P on OLG
progenitor migration corroborating other findings showing that each S1P receptor can
activate unique downstream signaling pathways, inspite of some redundancies in G-protein
coupling (Taha et al. 2004).
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Since FTY720, when phosphorylated to FTY720-P, does act on all S1P receptors
except on S1P2, it should also be considered that FTY720 could influence remyelination
by effects on other cells of the CNS (Miron et al. 2008c). In this regard, it was recently
demonstrated that (S)-FTY720-P has a direct effect on cultured astrocytes, stimulating both
their migration (Mullershausen et al. 2007) and ERK phosphorylation (Osinde et al. 2007)
via S1P receptors. Interestingly, astrocytes and other glial cells can be stimulated by S1P
to produce growth factors (Sato et al. 1999; Yamagata et al. 2003), an action that could
exert an indirect positive effect on the survival, proliferation and differentiation of OLG
progenitors and support the survival of neural cells.
Another cell type in the CNS which can potentially respond to FTY720 treatment is
the microglial population. Microglia are responsible for the phagocytosis of dying cells and
debris and regulate the innate and adaptive immune responses in the CNS. Although
studies have shown that macrophage infiltration into areas of traumatic brain injury is
blocked by FTY720 in rats (Zhang et al. 2007), it is yet unknown whether this mechanism
could impact microglial activation in the MS brain. Microglial reactivity in MS can lead to
positive effects by enhancing the production of growth factors or can have detrimental
consequences by increasing inflammatory cytokines (Gebicke-Haerter 2001; Streit 2002).
In pure microglial cultures, it was seen that S1P receptor mRNA levels varied depending
on the state of activation of the cells (Tham et al. 2003). This finding could be indicative of
a microglial mechanism of modulating gene expression profiles in response to
environmental signals.
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Another key finding of our study is that the positive effect of FTY720 on the
survival of OLG progenitors contrasted with an apparent inhibition of their maturation, an
effect that was counteracted by NT-3 (Coelho et al. 2007). As stated before, besides the
well documented roles of NT-3 in regulating OLG survival and proliferation (Barres et al.
1994b; Barres et al. 1993; Bertollini et al. 1997; Coelho et al. 2007; Johnson et al. 2000;
Kahn et al. 1999; Kumar et al. 1998; Robinson and Miller 1996; Wilson et al. 2003),
several lines of evidence also suggest that this neurotrophin plays a crucial function
modulating OLG maturation. Our finding that NT-3, as a potent enhancer of maturation,
can override the inhibitory effects of FTY720 further strengthen the studies done by
several other groups exploring the NT-3 mediated stimulation of maturation (Du et al.
2003; Heinrich et al. 1999; Jean et al. 2003; McTigue et al. 1998; Rubio et al. 2004; Yan
and Wood 2000).
However, little is known about the mechanisms underlying the maturational effect
of NT-3 on the OLGs.

To further decipher this problem, the second part of this thesis

investigated some of the mechanisms by which NT-3 could stimulate OLG differentiation
in particular, the expression of myelin proteins. We begun analyzing the effects of NT-3 on
the expression of MBP, a protein which is essential for myelin formation (Readhead et al.
1987). Alternative splicing of a single gene results in the generation of the different MBP
isoforms (de Ferra et al. 1985), a process that is developmentally regulated (Campagnoni
1988). The differential localization of the MBP isoforms in OLGs and myelin suggest that
some may be involved in cell differentiation while others are structural components of
myelin (Pedraza et al. 1997). Although we found that NT-3 causes a dramatic increase in

132
MBP expression in the cells, our studies could not attribute this effect to promoter gene
activation or upregulation of mRNA levels. Moreover, we found that the stimulatory
effect of NT-3 was not restricted to MBP but was also observed for MOG and MAG, two
very important myelin glycoproteins. MOG is found on the surface of myelinating OLGs
and external lamellae of myelin sheaths in the CNS (Amiguet et al. 1992; Birling et al.
1993; Brunner et al. 1989; Scolding et al. 1989) and it is a target antigen in EAE and MS.
This protein is expressed relatively late during brain development as compared to other
major myelin proteins (Matthieu and Amiguet 1990), a compelling factor determining the
role of MOG in the later stages of myelination to complete and maintain myelin integrity.
MAG, a glycoprotein particularly enriched in the periaxonal layers of the myelin sheath,
has been implicated in mediating axon-glial interactions and in controlling the initiation of
myelination (Quarles 2007).
The observation that NT-3 could upregulate MBP levels in the absence of
significant effects on MBP gene promoter activation or mRNA expression, together with
the fact that this neurotrophin also caused an increase in MOG and MAG, lead us to
hypothesize that NT-3 could have a more general effect on protein synthesis, perhaps
stimulating translation. This idea was further supported by the remarkable fast response
observed in the
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S-methionine incorporation assays indicating a 50% increase in protein

labeling even within only 15 min of exposure to NT-3. The mechanisms that regulate
protein translation in OLGs remain unknown. However, one could assume that they should
be crucial steps of control in OLG differentiation and myelin synthesis, particularly
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because as described below, there is localized translation of MBP mRNA occurring at the
tips of myelinating OLGs (Ainger et al. 1997; Barbarese et al. 1995).
Interestingly, as described in Chapter 3, we have found that NT -3 induces
phosphorylation of the initiation factor eIF4E, a mechanism that involves the MAPK and
Akt pathway. The regulated binding of eIF4E to the 7-methyl guanosine residue that caps
the 5‟ ends of all nuclear-encoded eukaryotic mRNAs marks the primary step of
translation. Interaction with 4EBP1 prevents the incorporation of eIF4E into an active
translational complex and thus, inhibits cap-dependent translation. This inhibitory signal
can be relieved following phosphorylation of 4EBP1. Importantly, we found that NT-3 can
also induce phosphorylation of this inhibitory binding molecule through a PI3K/mTOR
dependent pathway, an additional mechanism in play to stimulate translation initiation in
the OLGs.
To our knowledge these are the first studies investigating the regulation of
translational initiation in developing OLGs and the first report on a significant effect of
NT-3 as a regulator of the translation initiation machinery. Interestingly, we have
preliminary results suggesting that NT-3 may also play a role in the intracellular transport
of mRNAs.
Early observations showing that ribosomal subunits and MBP mRNA were present
in isolated purified myelin (Colman et al. 1982), suggesting that there was localized
translation of MBP mRNA in the myelin compartment. This finding was in agreement with
previous in situ hybridization studies which showed that MBP mRNAs are first localized
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in the cytoplasm of OLGs, even before myelination (Sternberger et al. 1978), and then
dispersed in the OLG processes at the beginning of myelination. Later studies provided
additional evidence to indicate that OLGs have an in-built mechanism to transport MBP
mRNAs selectively to regions within the cell where they will be necessary for the
compaction of myelin (Colman et al. 1982). Importantly, the myelin sheaths stain for MBP
mRNAs because the messages are transported through the cytoplasmic channels that
traverse the sheath. Spatial segregation of the MBP mRNAs begins only after the OLGs
have fully differentiated into myelinating cells as they must first have the cellular
processes in place before the MBP transport machinery can be activated (Verity and
Campagnoni 1988). Before that period, MBP is expressed throughout the cytoplasm and
even in the nucleus. However, all the isoforms do not behave in the same way when
individually expressed, as has been shown transfecting individual isoform cDNAs in the
shiverer OLG devoid of functional MBP (Allinquant et al. 1991) as already discussed
above.
The transport of MBP exon II containing mRNAs is an active process which
suggests that these particular isoforms are involved in a regulatory function in myelination
(Pedraza et al. 1997). The 14 kDa isoform (lacks exon II) is sufficient to create myelin
compaction in the CNS, as transgenic mice expressing only this isoform in the shiverer
mutant have compacted myelin (Kimura et al. 1989). Once the cytoplasmic extensions
form, the exon II lacking MBPs are upregulated and the mechanism of mRNA transport
can begin. Cytoskeletal elements may be involved in the dynamic process of MBP mRNA
transport (Ainger et al. 1997). It has been shown that MBP mRNA is transported in a
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translationally silenced state in RNA granules to the distal processes of cultured OLGs.
These granules contain RNA-binding proteins including heterogeneous nuclear ribonuclear
protein (hnRNP) A2. HnRNP A2, a member of the hnRNP A/B family, binds to a cisacting element in the MBP mRNA 3‟ untranslated region (UTR) termed the A2 response
element (Ainger et al. 1997; Munro et al. 1999). HnRNP A2 is thought to bind to MBP
mRNA in the nucleus, and the complex is then exported to the cytoplasm, where granules
are formed and transported in a micro-tubule dependent manner along the OLG processes
(Carson and Barbarese 2005). The formation of MBP-RNA-containing polysomes is
prevented, resulting in translational inhibition that must be relieved when the granule
reaches its destination (Kosturko et al. 2006).
The signals that result in the induction of localized translation of MBP mRNA
remain unknown, but because the timing of myelination is precisely regulated in
accordance with axonal maturation, it is likely that the signaling cascade from the neuronal
side of the axon-glia unit initiates the termination of translational repression of MBP
mRNA and the subsequent initiation of translation. It was found that steroids were able to
modulate the translation of the MBP message by a novel mechanism involving the steroid
modulatory element in the 5'-untranslated region of the MBP mRNA (Campagnoni et al.
1991).
Interestingly, our preliminary studies in which OLG progenitors were treated
overnight with NT-3 and later subjected to proteomic analysis, detected an increase in
several mRNA binding proteins, including hnRNP A/B (Table 4.1). This increase in
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Table 4.1: Proteomic analysis of proteins upregulated in OLGs after overnight
treatment with NT-3. OLG cultures were incubated overnight in the presence or absence
of 50 ng/ml NT-3. After detachment with Matrisperse solution, cells were lysed and
subjected to 2-dimensional differential in-gel electrophoresis (2-DIGE) followed by
computerized in-gel analysis to detect differential protein expression between untreated
and NT-3 treated cells. The spots of interest were subjected to mass spectrometry and the
proteins were identified through the NCBI database. Confidence intervals above 95% are
considered significant.
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Name of protein

Protein score (Confidence Interval %)

heterogeneous nuclear ribonucleoprotein U

100

N-ethylmaleimide sensitive fusion protein

85.61

heterogeneous nuclear ribonucleoprotein L

100

heterogeneous nuclear ribonucleoprotein type A/B

100

heterogeneous nuclear ribonucleoprotein A1

100

similar to Nsap1-pending protein

100

RNA terminal phosphate cyclase domain 1

100

similar to heterogeneous nuclear ribonucleoprotein 100
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Figure 4.1: NT-3 induces upregulation of hnRNP A/B in OLG progenitors. OLGs
were isolated from 3 day old rat brains and incubated for 24 hr in DMEM/F12 with or
without 10, 25, 50 ng/ml NT-3. hnRNP A/B levels were determined by western blot
analysis. -actin levels were used as loading controls. Western blot figures correspond to
representative experiments. Results are expressed as percentage of controls (0 ng/ml NT-3)
and represent the mean ± SEM from 2 independent experiments performed in triplicate.
*p<0.005
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hnRNP A/B expression was confirmed by Western Blot analysis with anti-hnRNP A/B
antibody (Figure 4.1).
Together with our previous results indicating a regulatory effect on components of
the initiation machinery, these findings strongly allude to the possibility that NT -3
stimulates protein synthesis in OLGs by affecting multiple posttranscriptional mechanisms.
In summary, several lines of evidence suggest a multifaceted role of NT-3 in OLG
development not only as a growth factor that acts through pathways of survival and
proliferation but also as a maturational stimulant, pushing immature progenitors towards
their ultimate function of myelination.

Moreover, our observations suggest that the

inclusion of a differentiating factor like NT-3 together with a survival drug like FTY720
would ensure both protection of existing OLG progenitor pools against immune-mediated
insults as well as stimulation of remyelination by enhancing the differentiation of these
cells.
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